COVID-19 vaccine effectiveness
(Randomized evidence)
Methods
Latest news:Last search date July 30, 2023. No further screening is planned after this date. Extraction is ongoing for all pending studies.
meta-COVID
Perform your own analysis using COVID-NMA data for prime vaccination (last search date 14/12/2022), create and download your forest plots by clicking below:
COVID-19 BOOSTER DOSE VACCINATION: updated daily
Vaccine efficacy, immunogenicity and safety of:
First Boost
- 1st booster VS no booster (tables)
- Immunogenicity
Geometric mean titre specific antibodies (D14)
Number of patients analyzed in intervention 1; N2: Number of patients analyzed in intervention 2; GMT1: Geometric mean titre for intervention 1; GMT2: Geometric mean titre for intervention 2; N1GMR: Geometric mean ratioReference Type of prime vaccination Prime schedule Intervention 1 Intervention 2 Follow up
daysParticipants GMT1(N1) GMT2(N2) GMR [95% CI] Evaluated by Risk of bias A B C D E Overall Hall VG, 2021 RNA based vaccine mRNA-1273 Boost mRNA-1273 Placebo 28 Transplant recipients 3,145
(60)86
(57)36.5 [ 12.9, 94] Roche Elecsys Vadrevu KM, 2022 Inactivated virus BBV152 Boost BBV152 Placebo 28 Adolescents and adults 7,013
(80)4,294
(87)1.56 [1.06, 2.28] ELISA
Geometric mean titre neutralization assay against wild type (D14)
Number of patients analyzed in intervention 1; N2: Number of patients analyzed in intervention 2; GMT1: Geometric mean titre for intervention 1; GMT2: Geometric mean titre for intervention 2; N1GMR: Geometric mean ratioReference Type of prime vaccination Prime schedule Intervention 1 Intervention 2 Follow up
daysParticipants GMT1(N1) GMT2(N2) GMR [95% CI] Evaluated by Risk of bias A B C D E Overall Vadrevu KM, 2022 Inactivated virus BBV152 Boost BBV152 Placebo 28 Adolescents and adults 746
(80)101
(87)7.41 [2.96, 18.51] PRNT Zhang Y, 2023 Inactivated virus CoronaVac Boost ChAdTS-S Placebo 14 Adults 290
(48)5
(46)56.8 [43.6, 74.1] Micro-neutralisation assay Zhang Y, 2023 Inactivated virus CoronaVac Boost RQ3013 Placebo 14 Adults 950
(46)5
(46)190.9 [145.8, 249.9] Micro-neutralisation assay Zhang Y, 2023 Inactivated virus CoronaVac Boost ZR202-CoV Placebo 14 Adults 635
(47)5
(46)120.8 [92.6, 157.6] Micro-neutralisation assay Zhang Y, 2023 Inactivated virus CoronaVac Boost CoronaVac Placebo 14 Adults 75
(46)5
(46)15.1 [11.5, 19.8] Micro-neutralisation assay Munro A, 2021 e Non replicating viral vector ChadOx1 Boost mRNA1273 Placebo 28 Adults, elderly, health care workers 2,368
(97)80
(101)26.98 [21.88, 33.26] PNA Munro A, 2021 e Non replicating viral vector ChadOx1 Boost CVnCov Placebo 28 Adults, elderly, health care workers 373
(99)80
(101)5.06 [4.11, 6.23] PNA Munro A, 2021 e Non replicating viral vector ChadOx1 Boost BNT162b2 half dose Placebo 28 Adults, elderly, health care workers 1,344
(103)80
(101)15.14 [12.32, 18.60] PNA Munro A, 2021 c Non replicating viral vector ChadOx1 Boost BNT162b2 Placebo 28 Adults, elderly, health care workers 1,621
(93)70
(91)21.58 [16.93, 27.51] PNA Munro A, 2021 c Non replicating viral vector ChadOx1 Boost VLA2001 Placebo 28 Adults, elderly, health care workers 202
(89)70
(91)2.68 [2.10, 3.43] PNA Munro A, 2021 c Non replicating viral vector ChadOx1 Boost VLA2001 half dose Placebo 28 Adults, elderly, health care workers 147
(95)70
(91)2.01 [1.57, 2.55] PNA Munro A, 2021 c Non replicating viral vector ChadOx1 Boost Ad26.COV2.S Placebo 28 Adults, elderly, health care workers 563
(95)70
(91)6.85 [5.37, 8.73] PNA Munro A, 2021 b RNA based vaccine BNT162b2 Boost ChadOx1 Placebo 28 Adults, elderly, health care workers 950
(98)157
(111)6.01 [4.87, 7.41] PNA Munro A, 2021 b RNA based vaccine BNT162b2 Boost Novavax Placebo 28 Adults, elderly, health care workers 766
(94)157
(111)5.39 [4.35, 6.67] PNA Munro A, 2021 b RNA based vaccine BNT162b2 Boost Novavax half dose Placebo 28 Adults, elderly, health care workers 606
(89)157
(111)3.50 [2.81, 4.36] PNA Munro A , 2021 a Non replicating viral vector ChadOx1 Boost ChadOx1 Placebo 28 Adults, elderly, health care workers 193
(98)85
(90)2.47 [1.96, 3.11] PNA Munro A , 2021 a Non replicating viral vector ChadOx1 Boost Novavax Placebo 28 Adults, elderly, health care workers 727
(87)85
(90)8.86 [7.00, 11.22] PNA Munro A , 2021 a Non replicating viral vector ChadOx1 Boost Novavax Boost ChadOx1 28 Adults, elderly, health care workers 727
(87)193
(98)8.86 [7.00, 11.22] PNA Munro A , 2021 a Non replicating viral vector ChadOx1 Boost Novavax half dose Boost ChadOx1 28 Adults, elderly, health care workers 470
(86)193
(98)5.89 [4.64, 7.46] PNA Munro A , 2021 a Non replicating viral vector ChadOx1 Boost Novavax half dose Placebo 28 Adults, elderly, health care workers 470
(86)85
(90)5.89 [4.64, 7.46] PNA Munro A, 2021 f RNA based vaccine BNT162b2 Boost mRNA1273 Placebo 28 Adults, elderly, health care workers 2,019
(91)175
(98)12.04 [9.95, 14.58] PNA Munro A, 2021 f RNA based vaccine BNT162b2 Boost CVnCov Placebo 28 Adults, elderly, health care workers 487
(91)175
(98)2.57 [2.13, 3.12] PNA Munro A, 2021 f RNA based vaccine BNT162b2 Boost BNT162b2 half dose Placebo 28 Adults, elderly, health care workers 1,339
(92)175
(98)6.91 [5.70, 8.37] PNA Munro A, 2021 d RNA based vaccine BNT162b2 Boost BNT162b2 Placebo 28 Adults, elderly, health care workers 1,789
(95)205
(93)8.35 [6.88, 10.14] PNA Munro A, 2021 d RNA based vaccine BNT162b2 Boost VLA2001 Placebo 28 Adults, elderly, health care workers 289
(91)205
(93)1.38 [1.14, 1.68] PNA Munro A, 2021 d RNA based vaccine BNT162b2 Boost VLA2001 half dose Placebo 28 Adults, elderly, health care workers 234
(87)205
(93)1.22 [1.00, 1.49] PNA Munro A, 2021 d RNA based vaccine BNT162b2 Boost Ad26.COV2.S Placebo 28 Adults, elderly, health care workers 1,441
(75)205
(93)7.84 [6.37, 9.64] PNA Wang X-Y, 2022 Inactivated virus BBIBP-CorV or CoronaVac Boost V-01 Placebo 14 Healthy adults 1,453
(199)157
(221)NR Live SARS-CoV-2 neutralization assay. Thuluva S, 2023 a Non replicating viral vector ChAdOx1 Boost BECOV2 Boost Placebo 28 Adults 6,317
(156)1,877
(52)3.37 [2.00, *] Plaque Reduction Neutralization Titer (PRNT)
Geometric mean titre neutralization assay against wild type (≥D90)
Number of patients analyzed in intervention 1; N2: Number of patients analyzed in intervention 2; GMT1: Geometric mean titre for intervention 1; GMT2: Geometric mean titre for intervention 2; N1GMR: Geometric mean ratioReference Type of prime vaccination Prime schedule Intervention 1 Intervention 2 Follow up
daysParticipants GMT1(N1) GMT2(N2) GMR [95% CI] Evaluated by Risk of bias A B C D E Overall Vadrevu KM, 2022 Inactivated virus BBV152 Boost BBV152 Placebo 180 Adolescents and adults 179
(31)11
(37)16.71 [3.31, 84.20] PRNT Zhang Y, 2023 Inactivated virus CoronaVac Boost ChAdTS-S Placebo 90 Adults 76
(48)4
(46)18.48 [15.01, 22.76] Micro-neutralisation assay Zhang Y, 2023 Inactivated virus CoronaVac Boost RQ3013 Placebo 90 Adults 124
(47)4
(46)30.31 [23.33, 39.38] Micro-neutralisation assay Zhang Y, 2023 Inactivated virus CoronaVac Boost ZR202-CoV Placebo 90 Adults 174
(47)4
(46)42.46 [32.36, 55.25] Micro-neutralisation assay Zhang Y, 2023 Inactivated virus CoronaVac Boost CoronaVac Placebo 90 Adults 19
(46)4
(46)4.51 [3.61, 5.62] Micro-neutralisation assay
Geometric mean titre neutralization assay against Omicron variant (D14)
Number of patients analyzed in intervention 1; N2: Number of patients analyzed in intervention 2; GMT1: Geometric mean titre for intervention 1; GMT2: Geometric mean titre for intervention 2; N1GMR: Geometric mean ratioReference Type of prime vaccination Prime schedule Intervention 1 Intervention 2 Follow up
daysParticipants GMT1(N1) GMT2(N2) GMR [95% CI] Evaluated by Risk of bias A B C D E Overall Zhang Y, 2023 Inactivated virus CoronaVac Boost ChAdTS-S Placebo 14 Adults 41
(48)4
(46)10.3 [7.6, 14.0] Micro-neutralisation assay Zhang Y, 2023 Inactivated virus CoronaVac Boost RQ3013 Placebo 14 Adults 247
(46)4
(46)62.4 [45.8, 85.1] Micro-neutralisation assay Zhang Y, 2023 Inactivated virus CoronaVac Boost ZR202-CoV Placebo 14 Adults 104
(47)4
(46)26.0 [19.1, 35.4] Micro-neutralisation assay Zhang Y, 2023 Inactivated virus CoronaVac Boost CoronaVac Placebo 14 Adults 8
(46)4
(46)2.0 [1.5, 2.7] Micro-neutralisation assay Hannawi S, 2022 Inactivated virus BBIBP-CorV Boost SCTV01C 20mcg Placebo 28 Adults 840
(74)58
(72)14.4 [10.3, 20.2] Plaque Reduction Neutralization Assay (PRNT50) Hannawi S, 2022 Inactivated virus BBIBP-CorV Boost SCTV01C 40mcg Placebo 28 Adults 901
(75)58
(72)15.0 [10.7, 21.1] Plaque Reduction Neutralization Assay (PRNT50)
Geometric mean titre neutralization assay against Omicron variant (≥D90)
Number of patients analyzed in intervention 1; N2: Number of patients analyzed in intervention 2; GMT1: Geometric mean titre for intervention 1; GMT2: Geometric mean titre for intervention 2; N1GMR: Geometric mean ratioReference Type of prime vaccination Prime schedule Intervention 1 Intervention 2 Follow up
daysParticipants GMT1(N1) GMT2(N2) GMR [95% CI] Evaluated by Risk of bias A B C D E Overall Zhang Y, 2023 Inactivated virus CoronaVac Boost ChAdTS-S Placebo 90 Adults 12
(48)4
(46)3.1 [2.4, 4.0] Micro-neutralisation assay Zhang Y, 2023 Inactivated virus CoronaVac Boost RQ3013 Placebo 90 Adults 38
(47)4
(46)9.4 [6.72, 13.14] Micro-neutralisation assay Zhang Y, 2023 Inactivated virus CoronaVac Boost ZR202-CoV Placebo 90 Adults 45
(47)4
(46)11.3 [8.32, 15.33] Micro-neutralisation assay Zhang Y, 2023 Inactivated virus CoronaVac Boost CoronaVac Placebo 90 Adults 5
(46)4
(46)1.17 [1.01, 1.36] Micro-neutralisation assay - Safety
Serious adverse events
r1: Number of events in intervention 1, r2: Number of events in intervention 2, N1: Number of patients analyzed in intervention 1; N2: Number of patients analyzed in intervention 2.Reference Type of prime vaccination Prime schedule Intervention 1 Intervention 2 Follow up
monthsParticipants r1/N1 r2/N2 RR [95% CI] Risk of bias A B C D E Overall Vadrevu KM, 2022 Inactivated virus BBV152 Boost BBV152 Placebo 1 Adolescents and adults 0 / 80 0 / 87 NR Tabarsi P, 2022 Any COVID-19 vaccine Any Covid-19 vaccine Boost SpikoGen Placebo 0.5 Adults 0 / 250 0 / 50 NR Zhang Y, 2023 Inactivated virus CoronaVac Boost ChAdTS-S Placebo 3 Adults 0 / 48 3 / 47 0.14
[0.01 - 2.63]Zhang Y, 2023 Inactivated virus CoronaVac Boost RQ3013 Placebo 3 Adults 0 / 47 3 / 47 0.14
[0.01 - 2.69]Zhang Y, 2023 Inactivated virus CoronaVac Boost ZR202-CoV Placebo 3 Adults 0 / 47 3 / 47 0.14
[0.01 - 2.69]Zhang Y, 2023 Inactivated virus CoronaVac Boost CoronaVac Placebo 3 Adults 0 / 46 3 / 47 0.15
[0.01 - 2.74]Moreira E D, 2022 RNA based vaccine BNT162b2 Boost BNT162b2 Placebo 2.5 Adults and adolescents 16 / 5055 24 / 5020 0.66
[0.35 - 1.24]Sung J, 2022 Any COVID-19 vaccine 2 doses BNT162b2 or BBIBP Boost Recombinant inactiv Bacillus subtilis spores Boost active adjuvant 1.2 Healthy adults 0 / 9 0 / 7 NR Hannawi S, 2022 Inactivated virus BBIBP-CorV Boost SCTV01C 20mcg Placebo 1 Adults 0 / 79 0 / 75 NR Hannawi S, 2022 Inactivated virus BBIBP-CorV Boost SCTV01C 40mcg Placebo 1 Adults 0 / 80 0 / 75 NR Munro A, 2021 e Non replicating viral vector ChadOx1 Boost mRNA1273 Placebo 2.7 Adults, elderly, health care workers 1 / 112 0 / 114 3.05
[0.13 - 74.16]Munro A, 2021 e Non replicating viral vector ChadOx1 Boost CVnCov Placebo 2.7 Adults, elderly, health care workers 0 / 119 0 / 114 NR Munro A, 2021 e Non replicating viral vector ChadOx1 Boost BNT162b2 half dose Placebo 2.7 Adults, elderly, health care workers 0 / 116 0 / 114 NR Munro A, 2021 c Non replicating viral vector ChadOx1 Boost BNT162b2 Placebo 2.7 Adults, elderly, health care workers 0 / 106 1 / 105 0.33
[0.01 - 8.01]Munro A, 2021 c Non replicating viral vector ChadOx1 Boost VLA2001 Placebo 2.7 Adults, elderly, health care workers 3 / 109 1 / 105 2.89
[0.31 - 27.34]Munro A, 2021 c Non replicating viral vector ChadOx1 Boost VLA2001 half dose Placebo 2.7 Adults, elderly, health care workers 0 / 111 1 / 105 0.32
[0.01 - 7.66]Munro A, 2021 c Non replicating viral vector ChadOx1 Boost Ad26.COV2.S Placebo 2.7 Adults, elderly, health care workers 1 / 108 1 / 105 0.97
[0.06 - 15.34]Munro A, 2021 b RNA based vaccine BNT162b2 Boost ChadOx1 Placebo 2.7 Adults, elderly, health care workers 0 / 109 1 / 118 0.36
[0.01 - 8.76]Munro A, 2021 b RNA based vaccine BNT162b2 Boost Novavax Placebo 2.7 Adults, elderly, health care workers 1 / 114 1 / 118 1.04
[0.07 - 16.35]Munro A, 2021 b RNA based vaccine BNT162b2 Boost Novavax half dose Placebo 2.7 Adults, elderly, health care workers 2 / 112 1 / 118 2.11
[0.19 - 22.91]Munro A , 2021 a Non replicating viral vector ChadOx1 Boost ChadOx1 Placebo 2.7 Adults, elderly, health care workers 1 / 111 0 / 109 2.95
[0.12 - 71.54]Munro A , 2021 a Non replicating viral vector ChadOx1 Boost Novavax Placebo 2.7 Adults, elderly, health care workers 0 / 115 0 / 109 NR Munro A , 2021 a Non replicating viral vector ChadOx1 Boost Novavax Boost ChadOx1 2.7 Adults, elderly, health care workers 0 / 115 1 / 111 0.32
[0.01 - 7.82]Munro A , 2021 a Non replicating viral vector ChadOx1 Boost Novavax half dose Boost ChadOx1 2.7 Adults, elderly, health care workers 0 / 108 1 / 111 0.34
[0.01 - 8.32]Munro A , 2021 a Non replicating viral vector ChadOx1 Boost Novavax half dose Placebo 2.7 Adults, elderly, health care workers 0 / 108 0 / 109 NR Munro A, 2021 f RNA based vaccine BNT162b2 Boost mRNA1273 Placebo 2.7 Adults, elderly, health care workers 0 / 110 0 / 112 NR Munro A, 2021 f RNA based vaccine BNT162b2 Boost CVnCov Placebo 2.7 Adults, elderly, health care workers 1 / 106 0 / 112 3.17
[0.13 - 76.94]Munro A, 2021 f RNA based vaccine BNT162b2 Boost BNT162b2 half dose Placebo 2.7 Adults, elderly, health care workers 0 / 110 0 / 112 NR Munro A, 2021 d RNA based vaccine BNT162b2 Boost BNT162b2 Placebo 2.7 Adults, elderly, health care workers 1 / 109 0 / 109 3
[0.12 - 72.84]Munro A, 2021 d RNA based vaccine BNT162b2 Boost VLA2001 Placebo 2.7 Adults, elderly, health care workers 0 / 110 0 / 109 NR Munro A, 2021 d RNA based vaccine BNT162b2 Boost VLA2001 half dose Placebo 2.7 Adults, elderly, health care workers 1 / 110 0 / 109 2.97
[0.12 - 72.18]Munro A, 2021 d RNA based vaccine BNT162b2 Boost Ad26.COV2.S Placebo 2.7 Adults, elderly, health care workers 0 / 106 0 / 109 NR Wang X-Y, 2022 Inactivated virus BBIBP-CorV or CoronaVac Boost V-01 Placebo NR Healthy adults 6 / 5108 8 / 5110 0.75
[0.26 - 2.16]Thuluva S, 2023 a Non replicating viral vector ChAdOx1 Boost BECOV2 Boost Placebo 6 Adults 0 / 156 0 / 52 NR
All-cause mortality
r1: Number of events in intervention 1, r2: Number of events in intervention 2, N1: Number of patients analyzed in intervention 1; N2: Number of patients analyzed in intervention 2.Reference Type of prime vaccination Prime schedule Intervention 1 Intervention 2 Follow up
monthsParticipants r1/N1 r2/N2 RR [95% CI] Risk of bias A B C D E Overall Zhang Y, 2023 Inactivated virus CoronaVac Boost ChAdTS-S Placebo 3 Adults 0 / 48 0 / 47 NR Zhang Y, 2023 Inactivated virus CoronaVac Boost RQ3013 Placebo 3 Adults 0 / 47 0 / 47 NR Zhang Y, 2023 Inactivated virus CoronaVac Boost ZR202-CoV Placebo 3 Adults 0 / 47 0 / 47 NR Zhang Y, 2023 Inactivated virus CoronaVac Boost CoronaVac Placebo 3 Adults 0 / 46 0 / 47 NR Hannawi S, 2022 Inactivated virus BBIBP-CorV Boost SCTV01C 20mcg Placebo 1 Adults 0 / 79 0 / 75 NR Hannawi S, 2022 Inactivated virus BBIBP-CorV Boost SCTV01C 40mcg Placebo 1 Adults 0 / 80 0 / 75 NR Vadrevu KM, 2022 Inactivated virus BBV152 Boost BBV152 Placebo 1 Adolescents and adults 0 / 80 0 / 87 NR Sung J, 2022 Any COVID-19 vaccine 2 doses BNT162b2 or BBIBP Boost Recombinant inactiv Bacillus subtilis spores Boost active adjuvant 1.2 Healthy adults 0 / 9 0 / 7 NR Toledo-Romani ME, 2022 b Protein subunit FINLAY-FR-2-25 mcg Boost FINLAY-FR-1-50 mcg Placebo 5.4 Adults 11 / 13883 24 / 14303 0.47
[0.23 - 0.96]Moreira E D, 2022 RNA based vaccine BNT162b2 Boost BNT162b2 Placebo 2.5 Adults and adolescents 0 / 5055 1 / 5020 0.33
[0.01 - 8.12]Wang X-Y, 2022 Inactivated virus BBIBP-CorV or CoronaVac Boost V-01 Placebo 2 Healthy adults 0 / 5108 0 / 5110 NR Thuluva S, 2023 a Non replicating viral vector ChAdOx1 Boost BECOV2 Boost Placebo 6 Adults 0 / 156 0 / 52 NR
- Immunogenicity
- 1st booster VS 1st booster (tables)
- Immunogenicity
Geometric mean titre specific antibodies (D14)
Number of patients analyzed in intervention 1; N2: Number of patients analyzed in intervention 2; GMT1: Geometric mean titre for intervention 1; GMT2: Geometric mean titre for intervention 2; N1GMR: Geometric mean ratioReference Type of prime vaccination Prime schedule Intervention 1 Intervention 2 Follow up
daysParticipants GMT1(N1) GMT2(N2) GMR [95% CI] Evaluated by Risk of bias A B C D E Overall Anderson E, 2022 RNA based vaccine mRNA-1273 Boost 50 mcg mRNA-1273.351 Boost 25 mcg mRNA-1273.351 and 25 mcg mRNA-1273 14 Healthy volunteers 9,591
(25)9,046
(22)1.06 [0.78, 1.43] 4-plex Mesoscale Discovery (MSD) 10-plex assay. Anderson E, 2022 RNA based vaccine mRNA-1273 Boost 100 mcg mRNA-1273 Boost 25 mcg mRNA-1273.351 and 25 mcg mRNA-1273 14 Healthy volunteers 8,396
(41)9,046
(22)0.93 [0.69, 1.24] 4-plex Mesoscale Discovery (MSD) 10-plex assay. Lien C, 2022 a Protein subunit MVC-COV1901 Boost MVC-COV1901-Beta 15 mcg Boost MVC-COV1901 14 Adults including healthy or stable co-morbidities 32,938
(12)25,879
(14)1.27 [0.70, 2.83] ELISA Lien C, 2022 a Protein subunit MVC-COV1901 Boost MVC-COV1901-Beta 25 mcg Boost MVC-COV1901 14 Adults including healthy or stable co-morbidities 43,209
(12)25,879
(14)1.66 [0.92, 3] ELISA Fadlyana E, 2023 Inactivated virus CoronaVac boost BNT162b2 boost CoronaVac 28 Healthy adults 18,289
(192)1,324
(190)13.81 [11.54, 16.54] Chemiluminescent microparticle immunoassay (CMIA) Fadlyana E, 2023 Inactivated virus CoronaVac boost BNT162b2 boost BNT162b2 28 Healthy adults 18,289
(192)18,289
(192)13.81 [11.54, 16.54] Chemiluminescent microparticle immunoassay (CMIA) Fadlyana E, 2023 Inactivated virus CoronaVac boost BNT162b2 (half dose) boost CoronaVac 28 Healthy adults 14,455
(185)1,324
(190)10.92 [9.00, 13.24] Chemiluminescent microparticle immunoassay (CMIA) Fadlyana E, 2023 Inactivated virus CoronaVac boost ChAdOx1 (half dose) boost CoronaVac 28 Healthy adults 7,267
(191)1,324
(190)5.49 [4.56, 6.11] Chemiluminescent microparticle immunoassay (CMIA) Launay O, 2022 RNA based vaccine BNT162b2 Boost MV B1.351 Boost BNT162b2 15 Adults including healthy or stable co-morbidities 2,241
(71)2,405
(76)0.93 [0.77, 1.13] ELISA Launay O, 2022 RNA based vaccine BNT162b2 Boost MV D614 Boost BNT162b2 15 Adults including healthy or stable co-morbidities 1,875
(76)2,405
(76)0.78 [0.65, 0.94] ELISA Li J, 2022 Inactivated virus CoronaVac Boost Ad5-vectored Boost Coronavac 14 Healthy adults 3,090
(96)369
(102)8.37 [6.52, 10.75] ELISA Costa Clemens SA, 2022 Inactivated virus CoronaVac Boost BNT162b2 Boost CoronaVac 28 Healthy adults 674,267
(333)48,405
(281)13.4 [11.6, 15.3] multiplex immunoassay Costa Clemens SA, 2022 Inactivated virus CoronaVac Boost ChAdOx1 Boost CoronaVac 28 Healthy adults 335,213
(296)48,405
(281)7.0 [6.1, 8.1] multiplex immunoassay Costa Clemens SA, 2022 Inactivated virus CoronaVac Boost AD26.COV2-S Boost CoronaVac 28 Healthy adults 336,851
(294)48,405
(281)6.7 [5.8, 7.7] multiplex immunoassay Cao Y, 2021 Inactivated virus CoronaVac Boost ZF2001 Boost CoronaVac 14 Healthcare workers 10,417
(81)7,496
(40)1.38 [*, *] ELISA Nanthapisal S, 2022 Inactivated virus 2 doses of CoronaVac 21-28 days apart Boost ChAdOx1-S standard dose Boost ChAdOx1-S low-dose 14 Healthy adults 1,975
(209)1,664
(209)1.19 [1.07, 1.31] ELISA Shinkai M, 2022 RNA based vaccine BNT162b2 Boost S-268019-b Boost BNT162b2 28 Adults 48,465
(101)55,215
(101)0.87 [0.72, 1.06] ELISA Jin L, 2022 Inactivated virus CoronaVac Boost Ad5-vectored high dose Boost CoronaVac 14 Healthy adults 6,175
(140)670
(140)9.21 [6.87, 12.35] ELISA Jin L, 2022 Inactivated virus CoronaVac Boost Ad5-vectored low dose Boost CoronaVac 14 Healthy adults 4,625
(140)670
(140)6.9 [5.01, 9.50] ELISA Chuang C-H, 2022 Non replicating viral vector ChAdOx1 Boost BNT162b2 Boost MVC-COV1901 28 Healthcare workers 524
(83)219
(85)2.39 [1.99, 2.86] ELISA Chuang C-H, 2022 Non replicating viral vector ChAdOx1 Boost mRNA-1273 (half dose) Boost MVC-COV1901 28 Healthcare workers 657
(85)219
(85)3 [2.52, 3.57] ELISA Chuang C-H, 2022 Non replicating viral vector ChAdOx1 Boost mRNA-1273 Boost MVC-COV1901 28 Healthcare workers 709
(85)219
(85)3.23 [2.72, 3.85] ELISA Sablerolles R, 2022 Non replicating viral vector Ad26.COV2.S Boost m-RNA-1273 Boost Ad26.COV2.S 28 Healthcare workers 4,379
(112)403
(106)10.86 [8.22, 14.34] Liaison SARS CoV-2 TrimericS IgG Sablerolles R, 2022 Non replicating viral vector Ad26.COV2.S Boost BNT162b2 Boost Ad26.COV2.S 28 Healthcare workers 2,671
(111)403
(106)6.62 [4.93, 8.89] Liaison SARS CoV-2 TrimericS IgG Estephan L, 2023 a Protein subunit MVC-COV1901 Boost 1/2 MVC-COV1901 Boost MVC-COV1901 28 Adults 17,526
(75)29,269
(75)0.60 [0.46, 0.78] ELISA Estephan L, 2023 a Protein subunit MVC-COV1901 Boost 1/2 mRNA-1273 Boost MVC-COV1901 28 Adults 85,648
(75)29,269
(75)2.93 [2.23, 3.83] ELISA Estephan L, 2023 a Protein subunit MVC-COV1901 Boost ChAdOx1 Boost MVC-COV1901 28 Adults 54,372
(77)29,269
(75)1.86 [1.42, 2.43] ELISA Estephan L, 2023 c RNA based vaccine mRNA-1273 Boost MVC-COV1901 Boost 1/2 mRNA-1273 28 Adults 17,944
(33)65,881
(44)0.27 [0.21, 0.36] ELISA Estephan L, 2023 c RNA based vaccine mRNA-1273 Boost ChAdOx1 Boost 1/2 mRNA-1273 28 Adults 36,618
(41)65,881
(44)0.55 [0.43, 0.72] ELISA Estephan L, 2023 c RNA based vaccine mRNA-1273 Boost 1/2 MVC-COV1901 Boost 1/2 mRNA-1273 28 Adults 18,678
(41)65,881
(44)0.28 [0.22, 0.37] ELISA Estephan L, 2023 b Non replicating viral vector ChadOx1 Boost MVC-COV1901 Boost ChadOx1 28 Adults 11,469
(75)4,924
(79)2.33 [1.84, 2.95] ELISA Estephan L, 2023 b Non replicating viral vector ChadOx1 Boost mRNA-1273 (half dose) Boost ChadOx1 28 Adults 55,310
(75)4,924
(79)11.23 [8.86, 14.24] ELISA
Geometric mean titre specific antibodies (≥D90)
Number of patients analyzed in intervention 1; N2: Number of patients analyzed in intervention 2; GMT1: Geometric mean titre for intervention 1; GMT2: Geometric mean titre for intervention 2; N1GMR: Geometric mean ratioReference Type of prime vaccination Prime schedule Intervention 1 Intervention 2 Follow up
daysParticipants GMT1(N1) GMT2(N2) GMR [95% CI] Evaluated by Risk of bias A B C D E Overall Jin L, 2022 Inactivated virus CoronaVac Boost Ad5-vectored high dose Boost CoronaVac 365 Healthy adults 1,452
(40)73
(40)19.96 [16.29, 25.71] ELISA Jin L, 2022 Inactivated virus CoronaVac Boost Ad5-vectored low dose Boost CoronaVac 365 Healthy adults 1,806
(40)73
(40)24.81 [20.24, 32.05] ELISA Sablerolles R, 2022 Non replicating viral vector Ad26.COV2.S Boost m-RNA-1273 Boost Ad26.COV2.S 150 Healthcare workers 746
(93)123
(85)6.07 [4.52, 8.13] Liaison SARS CoV-2 TrimericS IgG Sablerolles R, 2022 Non replicating viral vector Ad26.COV2.S Boost BNT162b2 Boost Ad26.COV2.S 150 Healthcare workers 544
(101)123
(85)4.42 [3.31, 5.92] Liaison SARS CoV-2 TrimericS IgG
Geometric mean titre neutralization assay against wild type (D14)
Number of patients analyzed in intervention 1; N2: Number of patients analyzed in intervention 2; GMT1: Geometric mean titre for intervention 1; GMT2: Geometric mean titre for intervention 2; N1GMR: Geometric mean ratioReference Type of prime vaccination Prime schedule Intervention 1 Intervention 2 Follow up
daysParticipants GMT1(N1) GMT2(N2) GMR [95% CI] Evaluated by Risk of bias A B C D E Overall Anderson E, 2022 RNA based vaccine mRNA-1273 Boost 50 mcg mRNA-1273.351 Boost 25 mcg mRNA-1273.351 and 25 mcg mRNA-1273 15 Healthy volunteers 2,111
(25)2,435
(22)0.87 [0.60, 1.24] Neutralization assay (PsVN) Anderson E, 2022 RNA based vaccine mRNA-1273 Boost 100 mcg mRNA-1273 Boost 25 mcg mRNA-1273.351 and 25 mcg mRNA-1273 15 Healthy volunteers 2,842
(41)2,435
(22)1.17 [0.84, 1.62] Neutralization assay (PsVN) Al Kaabi N, 2022 b Inactivated virus BBIBP-CorV Boost NVSI-06-08 4-6 months Boost BBIBP-CorV 4-6 months 15 Healthy adults 3,142
(285)197
(289)15.96 [13.34, 19.08] Live-virus neutralization assay Al Kaabi N, 2022 b Inactivated virus BBIBP-CorV Boost NVSI-06-08 7-9 months Boost BBIBP-CorV 7-9 months 15 Healthy adults 4,908
(270)505
(270)9.72 [8.04, 11.77] Live-virus neutralization assay Al Kaabi N, 2022 b Inactivated virus BBIBP-CorV Boost NVSI-06-08 >9 months Boost BBIBP-CorV >9 months 15 Healthy adults 4,185
(286)375
(278)11.17 [9.44, 13.22] Live-virus neutralization assay Lien C, 2022 a Protein subunit MVC-COV1901 Boost MVC-COV1901-Beta 15 mcg Boost MVC-COV1901 28 Adults including healthy or stable co-morbidities 1,805
(12)1,352
(14)1.33 [0.61, 2.89] Plaque reduction neutralization test Lien C, 2022 a Protein subunit MVC-COV1901 Boost MVC-COV1901-Beta 25 mcg Boost MVC-COV1901 28 Adults including healthy or stable co-morbidities 3,603
(12)1,352
(14)2.64 [1.22, 5.79] Plaque reduction neutralization test Amplify, 2023 b RNA based vaccine BNT162b2 Boost Ad26.COV2.S 1*10^10 vp Boost Ad26.COV2.S 5*10^10 vp 14 Adults including elderly and stable co-morbidities 3,218
(88)4,439
(299)0.725 [0.570, 0.922] Virus neutralization assay (VNA) Amplify, 2023 b RNA based vaccine BNT162b2 Boost Ad26.COV2.S 2.5*10^10 vp Boost Ad26.COV2.S 5*10^10 vp 14 Adults including elderly and stable co-morbidities 3,566
(295)4,439
(299)0.803 [0.696, 0.927] Virus neutralization assay (VNA) Amplify, 2023 a Non replicating viral vector Ad26.COV2.S Boost Ad26.COV2.S 1*10^10 vp Boost Ad26.COV2.S 5*10^10 vp 14 Adults including elderly and stable co-morbidities 734
(93)1,130
(298)0.649 [0.484, 0.827] Virus neutralization assay (VNA) Amplify, 2023 a Non replicating viral vector Ad26.COV2.S Boost Ad26.COV2.S 2.5*10^10 vp Boost Ad26.COV2.S 5*10^10 vp 14 Adults including elderly and stable co-morbidities 915
(297)1,130
(298)0.810 [0.665, 0.986] Virus neutralization assay (VNA) Al Kaabi N, 2023 Inactivated virus BBIBP-CorV Boost NVSI-06-09 Boost BBIBP-CorV 14 Healthy adults 2,349
(255)506
(249)4.64 [3.93, 5.47] Live-virus microneutralization assay Niyomnaitham S, 2022 Inactivated virus CoronaVac Boost ChAdOx1 (1/5 dose ID) Boost BNT162b2 (1/6 dose ID) 14 Healthy adults 206
(45)288
(45)0.71 [0.48, 1.07] Plaque reduction neutralization test Rao C, 2022 Inactivated virus CoronaVac Boost SCB-2019 Boost CoronaVac 14 Adults who are healthy or have a stable pre-existing medical condition 744
(209)164
(211)4.63 [3.96, 5.41] Microneutralization assay Niyomnaitham S, 2023 Inactivated virus Coronavac Boost ChAdOx1 Boost BNT162b2 28 Healthy adults 575
(97)928
(99)NR Micro Neutralizing Antibody Titer Omma A, 2022 Inactivated virus CoronaVac Boost TURKOVAC Boost CoronaVac 28 Adults 34
(104)28
(114)1.45 [0.36, 5.80] Microneutralization test (MNT) Launay O, 2022 RNA based vaccine BNT162b2 Boost MV B1.351 Boost BNT162b2 15 Adults including healthy or stable co-morbidities 1,801
(71)1,364
(76)1.32 [0.95, 1.83] Microneutralization test Launay O, 2022 RNA based vaccine BNT162b2 Boost MV D614 Boost BNT162b2 15 Adults including healthy or stable co-morbidities 1,168
(76)1,364
(76)0.86 [0.62, 1.18] Microneutralization test Li J, 2022 Inactivated virus CoronaVac Boost Ad5-vectored Boost Coronavac 14 Healthy adults 197
(96)34
(102)5.9 [4.5, 7.7] Cytopathic effect-based microneutralization assay- wild-type SARS-CoV-2 Cao Y, 2021 Inactivated virus CoronaVac Boost ZF2001 Boost CoronaVac 14 Healthcare workers 1,306
(81)794
(40)1.64 [1.09, 2.46] CPE Nanthapisal S, 2022 Inactivated virus 2 doses of CoronaVac 21-28 days apart Boost ChAdOx1-S standard dose Boost ChAdOx1-S low-dose 14 Healthy adults 96
(207)97
(203)0.99 [0.97, 1.01] Virus neutralization test (sVNT) Shinkai M, 2022 RNA based vaccine BNT162b2 Boost S-268019-b Boost BNT162b2 14 Adults 128
(101)139
(101)0.94 [0.76, 1.09] Cytopathic effect-based virus neutralization test Mok C K P, 2022 Inactivated virus CoronaVac Boost CoronaVac Boost BNT162b2 30 Adults 17
(40)207
(40)NR PRNT90 Toledo-Romani ME, 2022 a Protein subunit FINLAY-FR-2-25 mcg Boost FR-1 Boost FINLAY-FR-2 28 Healthy adults 43
(55)33
(51)1.29 [0.81, 2.06] Conventional virus neutralization test Assantachai P, 2023 Non replicating viral vector ChAdOx1 Boost mRNA-1273 20 mcg ID Boost mRNA-1273 14-28 Adults 1,212
(35)1,718
(35)0.70 [0.40, 1.23] Pseudovirus neutralization test assay Assantachai P, 2023 Non replicating viral vector ChAdOx1 Boost BNT162b2 10 mcg ID Boost BNT162b2 14-28 Adults 587
(68)713
(68)0.82 [0.51, 1.31] Pseudovirus neutralization test assay Corominas J, 2023 RNA based vaccine BNT162b2 Boost PHH-1V Boost BNT162b2 14 Healthy adults 1,966
(500)3,309
(241)0.59 [0.51, 0.69] PNA Jin L, 2022 Inactivated virus CoronaVac Boost Ad5-vectored high dose Boost CoronaVac 28 Healthy adults 1,635
(40)70
(40)23.42 [19.05, 30.40] CPE-based microneutralisation Jin L, 2022 Inactivated virus CoronaVac Boost Ad5-vectored low dose Boost CoronaVac 28 Healthy adults 1,911
(40)70
(40)27.40 [22.27, 35.39] CPE-based microneutralisation Wang L, 2022 Inactivated virus CoronaVac Boost CoronaVac 1.5 10m Boost CoronaVax 1.5 12m 28 Children and adolescents 598
(85)462
(85)1.29 [0.89, 1.86] Micro cytopathic effect assay Wang L, 2022 Inactivated virus CoronaVac Boost CoronaVax 3 10m Boost CoronaVax 3 12m 28 Children and adolescents 681
(85)754
(82)0.91 [0.64, 1.28] Micro cytopathic effect assay Sablerolles R, 2022 Non replicating viral vector Ad26.COV2.S Boost m-RNA-1273 Boost Ad26.COV2.S 28 Healthcare workers 5,686
(11)614
(12)9.26 [5.20, 16.48] PRNT Sablerolles R, 2022 Non replicating viral vector Ad26.COV2.S Boost BNT162b2 Boost Ad26.COV2.S 28 Healthcare workers 2,204
(12)614
(12)3.58 [1.11, 11.59] PRNT Estephan L, 2023 a Protein subunit MVC-COV1901 Boost 1/2 MVC-COV1901 Boost MVC-COV1901 28 Adults 985
(75)1,690
(75)0.58 [0.43, 0.79] Live virus neutralization assay Estephan L, 2023 a Protein subunit MVC-COV1901 Boost 1/2 mRNA-1273 Boost MVC-COV1901 28 Adults 5,934
(75)1,690
(75)3.51 [2.59, 4.76] Live virus neutralization assay Estephan L, 2023 a Protein subunit MVC-COV1901 Boost ChAdOx1 Boost MVC-COV1901 28 Adults 3,835
(77)1,690
(75)2.27 [1.67, 3.07] Live virus neutralization assay Estephan L, 2023 c RNA based vaccine mRNA-1273 Boost MVC-COV1901 Boost 1/2 mRNA-1273 28 Adults 735
(33)2,635
(44)0.28 [0.19, 0.40] Live virus neutralization assay Estephan L, 2023 c RNA based vaccine mRNA-1273 Boost ChAdOx1 Boost 1/2 mRNA-1273 28 Adults 1,632
(41)2,635
(44)0.62 [0.44, 0.87] Live virus neutralization assay Estephan L, 2023 c RNA based vaccine mRNA-1273 Boost 1/2 MVC-COV1901 Boost 1/2 mRNA-1273 28 Adults 577
(41)2,635
(44)0.22 [0.16, 0.31] Live virus neutralization assay Estephan L, 2023 b Non replicating viral vector ChadOx1 Boost MVC-COV1901 Boost ChadOx1 28 Adults 673
(75)232
(79)2.90 [2.22, 3.80] Live virus neutralization assay Estephan L, 2023 b Non replicating viral vector ChadOx1 Boost mRNA-1273 (half dose) Boost ChadOx1 28 Adults 3,121
(75)232
(79)13.48 [10.30, 17.62] Live virus neutralization assay Leung N, 2022 RNA based vaccine BNT162b2 Boost CoronaVac Boost BNT162b2 28 Adults including co-morbidities 92
(20)816
(20)NR Live virus plaque reduction neutralization test PRNT50 Leung N, 2022 Inactivated virus CoronaVac Boost BNT162b2 Boost CoronaVac 28 Adults including co-morbidities 905
(20)109
(20)NR Live virus plaque reduction neutralization test PRNT50 Jin P, 2023 a Inactivated virus CoronaVac Boost Ad5-vectored 5×10^10 vp Boost CoronaVac 14 Elderly 286
(50)48
(50)5.94 [4.61, 7.65] Microneutralization assay Kulkarni P, 2023 a Non replicating viral vector ChAdOx1 Boost SII-NVX-CoV2373 Boost ChAdOx1 29 Adults 3,963
(92)2,032
(93)1.95 [1.52, 2.50] Microneutralization assay (MN) Kulkarni P , 2023 b Inactivated virus BBV152 Boost SII-NVX-CoV2373 Boost BBV152 29 Adults 2,848
(91)516
(93)5.5 [4, 7.8] Microneutralization assay (MN)
Geometric mean titre neutralization assay against wild type (≥D90)
Number of patients analyzed in intervention 1; N2: Number of patients analyzed in intervention 2; GMT1: Geometric mean titre for intervention 1; GMT2: Geometric mean titre for intervention 2; N1GMR: Geometric mean ratioReference Type of prime vaccination Prime schedule Intervention 1 Intervention 2 Follow up
daysParticipants GMT1(N1) GMT2(N2) GMR [95% CI] Evaluated by Risk of bias A B C D E Overall Niyomnaitham S, 2023 Inactivated virus Coronavac Boost ChAdOx1 Boost BNT162b2 90 Healthy adults 309
(97)363
(99)NR Micro Neutralizing Antibody Titer Corominas J, 2023 RNA based vaccine BNT162b2 Boost PHH-1V Boost BNT162b2 98 Healthy adults 1,120
(78)960
(42)1.16 [0.82, 1.66] PNA Jin L, 2022 Inactivated virus CoronaVac Boost Ad5-vectored high dose Boost CoronaVac 365 Healthy adults 171
(40)8
(40)21.41 [12.77, 66.23] CPE-based microneutralisation Jin L, 2022 Inactivated virus CoronaVac Boost Ad5-vectored low dose Boost CoronaVac 365 Healthy adults 204
(40)8
(40)25.58 [79.37, 15.22] CPE-based microneutralisation Sablerolles R, 2022 Non replicating viral vector Ad26.COV2.S Boost m-RNA-1273 Boost Ad26.COV2.S 150 Healthcare workers 822
(11)293
(12)2.80 [1.15, 6.83] PRNT Sablerolles R, 2022 Non replicating viral vector Ad26.COV2.S Boost BNT162b2 Boost Ad26.COV2.S 150 Healthcare workers 748
(12)293
(12)2.55 [1.27, 5.11] PRNT
Geometric mean titre neutralization assay against Omicron variant (D14)
Number of patients analyzed in intervention 1; N2: Number of patients analyzed in intervention 2; GMT1: Geometric mean titre for intervention 1; GMT2: Geometric mean titre for intervention 2; N1GMR: Geometric mean ratioReference Type of prime vaccination Prime schedule Intervention 1 Intervention 2 Follow up
daysParticipants GMT1(N1) GMT2(N2) GMR [95% CI] Evaluated by Risk of bias A B C D E Overall Al Kaabi N, 2022 b Inactivated virus BBIBP-CorV Boost NVSI-06-08 7-9 months Boost BBIBP-CorV 7-9 months 15 Healthy adults 368
(270)45
(270)8.17 [6.03, 11.06] Live-virus neutralization assay Lien C, 2022 a Protein subunit MVC-COV1901 Boost MVC-COV1901-Beta 15 mcg Boost MVC-COV1901 28 Adults including healthy or stable co-morbidities 240
(12)139
(14)1.72 [0.76, 3.91] Pseudovirus neutralisation assay. Lien C, 2022 a Protein subunit MVC-COV1901 Boost MVC-COV1901-Beta 25 mcg Boost MVC-COV1901 28 Adults including healthy or stable co-morbidities 426
(12)139
(14)3.05 [1.44, 6.47] Pseudovirus neutralisation assay. Al Kaabi N, 2023 Inactivated virus BBIBP-CorV Boost NVSI-06-09 Boost BBIBP-CorV 14 Healthy adults 1,714
(255)143
(249)11.96 [9.60, 14.90] Live-virus neutralizing antibody response against Omicron (BA.1.1) variant (PPS) Niyomnaitham S, 2022 Inactivated virus CoronaVac Boost ChAdOx1 (1/5 dose ID) Boost BNT162b2 (1/6 dose ID) 14 Healthy adults 46
(45)53
(45)0.87 [0.55, 1.38] Plaque reduction neutralization test (PRNT50) Rao C, 2022 Inactivated virus CoronaVac Boost SCB-2019 Boost CoronaVac 14 Adults who are healthy or have a stable pre-existing medical condition 253
(209)73
(211)3.45 [2.70, 4.42] Microneutralization assay Niyomnaitham S, 2023 Inactivated virus Coronavac Boost ChAdOx1 Boost BNT162b2 28 Healthy adults 119
(97)256
(99)0.46 [0.36, 0.59] Pseudovirus Neutralizing Antibody Titers (PVNT50) Launay O, 2022 RNA based vaccine BNT162b2 Boost MV B1.351 Boost BNT162b2 15 Adults including healthy or stable co-morbidities 253
(71)140
(76)1.81 [1.34, 2.44] Microneutralization test Launay O, 2022 RNA based vaccine BNT162b2 Boost MV D614 Boost BNT162b2 15 Adults including healthy or stable co-morbidities 124
(76)140
(76)0.88 [0.67, 1.17] Microneutralization test Costa Clemens SA, 2022 Inactivated virus CoronaVac Boost BNT162b2 Boost CoronaVac 28 Healthy adults 223
(20)17
(20)13.12 [5.66, 30.40] Live-virus neutralization assay against Omicron Costa Clemens SA, 2022 Inactivated virus CoronaVac Boost ChAdOx1 Boost CoronaVac 28 Healthy adults 102
(20)17
(20)6 [2.91, 12.36] Live-virus neutralization assay against Omicron Costa Clemens SA, 2022 Inactivated virus CoronaVac Boost AD26.COV2-S Boost CoronaVac 28 Healthy adults 138
(20)17
(20)8.12 [3.72, 17.69] Live-virus neutralization assay against Omicron Assantachai P, 2023 Non replicating viral vector ChAdOx1 Boost mRNA-1273 20 mcg ID Boost mRNA-1273 14-28 Adults 318
(35)617
(35)0.51 [0.29, 0.92] Pseudovirus neutralization test assay Assantachai P, 2023 Non replicating viral vector ChAdOx1 Boost BNT162b2 10 mcg ID Boost BNT162b2 14-28 Adults 148
(68)230
(68)0.64 [0.42, 0.98] Pseudovirus neutralization test assay Corominas J, 2023 RNA based vaccine BNT162b2 Boost PHH-1V Boost BNT162b2 14 Healthy adults 2,036
(500)1,211
(241)1.70 [1.41, 2] Pseudovirion-based neutralisation assay (PBNA) Jin L, 2022 Inactivated virus CoronaVac Boost Ad5-vectored high dose Boost CoronaVac 28 Healthy adults 23
(40)4
(40)5.67 [3.01, 47.85] Cyto-pathic effect-based microneutralization assay Jin L, 2022 Inactivated virus CoronaVac Boost Ad5-vectored low dose Boost CoronaVac 28 Healthy adults 52
(40)4
(40)12.77 [6.61, 188.68] Cyto-pathic effect-based microneutralization assay Wang L, 2022 Inactivated virus CoronaVac Boost CoronaVac 1.5 10m Boost CoronaVax 1.5 12m 28 Children and adolescents 24
(85)24
(85)0.93 [0.65, 1.47] micro cytopathogenic effect assay Wang L, 2022 Inactivated virus CoronaVac Boost CoronaVax 3 10m Boost CoronaVax 3 12m 28 Children and adolescents 35
(85)40
(82)0.86 [0.60, 1.23] micro cytopathogenic effect assay Chuang C-H, 2022 Non replicating viral vector ChAdOx1 Boost BNT162b2 Boost MVC-COV1901 28 Healthcare workers 146
(30)37
(30)NR Live virus neutralization Chuang C-H, 2022 Non replicating viral vector ChAdOx1 Boost mRNA-1273 (half dose) Boost MVC-COV1901 28 Healthcare workers 204
(30)37
(30)5.51 [3.42, 8.90] Live virus neutralization Chuang C-H, 2022 Non replicating viral vector ChAdOx1 Boost mRNA-1273 Boost MVC-COV1901 28 Healthcare workers 250
(30)37
(30)6.75 [4.30, 10.61] Live virus neutralization Estephan L, 2023 a Protein subunit MVC-COV1901 Boost 1/2 MVC-COV1901 Boost MVC-COV1901 28 Adults 195
(75)247
(75)NR Pseudovirus neutralizing assay Estephan L, 2023 a Protein subunit MVC-COV1901 Boost 1/2 mRNA-1273 Boost MVC-COV1901 28 Adults 955
(75)247
(75)NR Pseudovirus neutralizing assay Estephan L, 2023 a Protein subunit MVC-COV1901 Boost ChAdOx1 Boost MVC-COV1901 28 Adults 661
(77)247
(75)NR Pseudovirus neutralizing assay Estephan L, 2023 c RNA based vaccine mRNA-1273 Boost MVC-COV1901 Boost 1/2 mRNA-1273 28 Adults 105
(33)658
(44)NR Pseudovirus neutralizing assay Estephan L, 2023 c RNA based vaccine mRNA-1273 Boost ChAdOx1 Boost 1/2 mRNA-1273 28 Adults 657
(41)658
(44)NR Pseudovirus neutralizing assay Estephan L, 2023 c RNA based vaccine mRNA-1273 Boost 1/2 MVC-COV1901 Boost 1/2 mRNA-1273 28 Adults 68
(41)658
(44)NR Pseudovirus neutralizing assay Estephan L, 2023 b Non replicating viral vector ChadOx1 Boost MVC-COV1901 Boost ChadOx1 28 Adults 63
(75)27
(79)NR Pseudovirus neutralizing assay Estephan L, 2023 b Non replicating viral vector ChadOx1 Boost mRNA-1273 (half dose) Boost ChadOx1 28 Adults 651
(75)27
(79)NR Pseudovirus neutralizing assay Leung N, 2022 RNA based vaccine BNT162b2 Boost CoronaVac Boost BNT162b2 28 Adults including co-morbidities 6
(20)67
(20)NR Live virus plaque reduction neutralization test PRNT50 Leung N, 2022 Inactivated virus CoronaVac Boost BNT162b2 Boost CoronaVac 28 Adults including co-morbidities 80
(20)6
(20)NR Live virus plaque reduction neutralization test PRNT50 Jin P, 2023 a Inactivated virus CoronaVac Boost Ad5-vectored 5×10^10 vp Boost CoronaVac 14 Elderly 33
(50)4
(50)7.5 [4.7, 11.9] Microneutralization assay Kulkarni P, 2023 a Non replicating viral vector ChAdOx1 Boost SII-NVX-CoV2373 Boost ChAdOx1 29 Adults 165
(92)87
(93)1.89 [1.04, 3.45] Microneutralization assay (MN) Kulkarni P , 2023 b Inactivated virus BBV152 Boost SII-NVX-CoV2373 Boost BBV152 29 Adults 194
(91)41
(93)4.72 [2.54, 8.77] Microneutralization assay (MN) Li X, 2023 Inactivated virus Any inactivated COVID-19 vaccine Boost aerosolized Ad5-nCoV Boost CoronaVac Healthy volunteers 91
(*)19
(*)4.78 [3.84, 5.96] Pseudovirus neutralization test
Geometric mean titre neutralization assay against Omicron variant (≥D90)
Number of patients analyzed in intervention 1; N2: Number of patients analyzed in intervention 2; GMT1: Geometric mean titre for intervention 1; GMT2: Geometric mean titre for intervention 2; N1GMR: Geometric mean ratioReference Type of prime vaccination Prime schedule Intervention 1 Intervention 2 Follow up
daysParticipants GMT1(N1) GMT2(N2) GMR [95% CI] Evaluated by Risk of bias A B C D E Overall Corominas J, 2023 RNA based vaccine BNT162b2 Boost PHH-1V Boost BNT162b2 98 Healthy adults 618
(78)349
(42)1.75 [1.22, 2.56] Pseudovirion-based neutralisation assay (PBNA) Jin L, 2022 Inactivated virus CoronaVac Boost Ad5-vectored high dose Boost CoronaVac 180 Healthy adults 12
(40)4
(40)2.95 [1.65, 14.01] Cyto-pathic effect-based microneutralization assay Jin L, 2022 Inactivated virus CoronaVac Boost Ad5-vectored low dose Boost CoronaVac 180 Healthy adults 16
(40)4
(40)3.93 [2.14, 24.39] Cyto-pathic effect-based microneutralization assay - Safety
Serious adverse events
r1: Number of events in intervention 1, r2: Number of events in intervention 2, N1: Number of patients analyzed in intervention 1; N2: Number of patients analyzed in intervention 2.Reference Type of prime vaccination Prime schedule Intervention 1 Intervention 2 Follow up
monthsParticipants r1/N1 r2/N2 RR [95% CI] Risk of bias A B C D E Overall Anderson E, 2022 RNA based vaccine mRNA-1273 Boost 50 mcg mRNA-1273.351 Boost 25 mcg mRNA-1273.351 and 25 mcg mRNA-1273 1 Healthy volunteers 0 / 25 1 / 23 0.31
[0.01 - 7.16]Anderson E, 2022 RNA based vaccine mRNA-1273 Boost 100 mcg mRNA-1273 Boost 25 mcg mRNA-1273.351 and 25 mcg mRNA-1273 1 Healthy volunteers 0 / 48 1 / 23 0.16
[0.01 - 3.81]Lien C, 2022 a Protein subunit MVC-COV1901 Boost MVC-COV1901-Beta 15 mcg Boost MVC-COV1901 0.9 Adults including healthy or stable co-morbidities 0 / 15 0 / 15 NR Lien C, 2022 a Protein subunit MVC-COV1901 Boost MVC-COV1901-Beta 25 mcg Boost MVC-COV1901 0.9 Adults including healthy or stable co-morbidities 0 / 15 0 / 15 NR Amplify, 2023 b RNA based vaccine BNT162b2 Boost Ad26.COV2.S 1*10^10 vp Boost Ad26.COV2.S 5*10^10 vp 4.5 Adults including elderly and stable co-morbidities 1 / 106 3 / 326 1.03
[0.11 - 9.75]Amplify, 2023 b RNA based vaccine BNT162b2 Boost Ad26.COV2.S 2.5*10^10 vp Boost Ad26.COV2.S 5*10^10 vp 4.5 Adults including elderly and stable co-morbidities 1 / 326 3 / 326 0.33
[0.03 - 3.19]Amplify, 2023 a Non replicating viral vector Ad26.COV2.S Boost Ad26.COV2.S 1*10^10 vp Boost Ad26.COV2.S 5*10^10 vp 4.5 Adults including elderly and stable co-morbidities 0 / 116 1 / 330 0.95
[0.04 - 23.05]Amplify, 2023 a Non replicating viral vector Ad26.COV2.S Boost Ad26.COV2.S 2.5*10^10 vp Boost Ad26.COV2.S 5*10^10 vp 4.5 Adults including elderly and stable co-morbidities 3 / 328 1 / 330 3.02
[0.32 - 28.87]Fadlyana E, 2023 Inactivated virus CoronaVac boost BNT162b2 boost CoronaVac 28 Healthy adults 1 / 193 0 / 191 2.97
[0.12 - 72.43]Fadlyana E, 2023 Inactivated virus CoronaVac boost BNT162b2 boost BNT162b2 28 Healthy adults 1 / 193 1 / 193 1
[0.06 - 15.87]Fadlyana E, 2023 Inactivated virus CoronaVac boost BNT162b2 (half dose) boost CoronaVac 28 Healthy adults 0 / 186 0 / 191 NR Fadlyana E, 2023 Inactivated virus CoronaVac boost ChAdOx1 (half dose) boost CoronaVac 28 Healthy adults 1 / 192 0 / 191 2.98
[0.12 - 72.8]Al Kaabi N, 2023 Inactivated virus BBIBP-CorV Boost NVSI-06-09 Boost BBIBP-CorV 1 Healthy adults 0 / 260 0 / 256 NR Rao C, 2022 Inactivated virus CoronaVac Boost SCB-2019 Boost CoronaVac 2.0 Adults who are healthy or have a stable pre-existing medical condition 0 / 214 1 / 216 0.34
[0.01 - 8.21]Niyomnaitham S, 2023 Inactivated virus Coronavac Boost ChAdOx1 Boost BNT162b2 3 Healthy adults 0 / 307 0 / 308 NR Tawinprai K, 2022 Inactivated virus CoronaVac Boost ChAdOx1 Boost BBIBP-CorV 0.5 Adults without active underlying disease 0 / 41 0 / 40 NR Omma A, 2022 Inactivated virus CoronaVac Boost TURKOVAC Boost CoronaVac 1 Adults 0 / 108 1 / 114 0.35
[0.01 - 8.54]Launay O, 2022 RNA based vaccine BNT162b2 Boost MV B1.351 Boost BNT162b2 0.5 Adults including healthy or stable co-morbidities 1 / 80 0 / 82 3.07
[0.13 - 74.36]Launay O, 2022 RNA based vaccine BNT162b2 Boost MV D614 Boost BNT162b2 0.5 Adults including healthy or stable co-morbidities 1 / 85 0 / 82 2.89
[0.12 - 70.04]Poh XY, 2022 RNA based vaccine BNT162b2 Boost mRNA-1273 Boost BNT162b2 28 Adults 0 / 48 0 / 50 NR Li J, 2022 Inactivated virus CoronaVac Boost Ad5-vectored Boost Coronavac 1 Healthy adults 0 / 96 0 / 102 NR Reindl-Schwaighofer R, 2021 RNA based vaccine BNT162b2 or mRNA-1273 Boost BNT162b2 or mRNA-1273 Boost Ad26COVS1 1 Kidney transplant recipients 2 / 99 3 / 99 0.67
[0.11 - 3.9]Costa Clemens SA, 2022 Inactivated virus CoronaVac Boost BNT162b2 Boost CoronaVac 1 Healthy adults 1 / 339 0 / 291 2.58
[0.11 - 62.99]Costa Clemens SA, 2022 Inactivated virus CoronaVac Boost ChAdOx1 Boost CoronaVac 1 Healthy adults 1 / 304 0 / 291 2.87
[0.12 - 70.22]Costa Clemens SA, 2022 Inactivated virus CoronaVac Boost AD26.COV2-S Boost CoronaVac 1 Healthy adults 3 / 305 0 / 291 6.68
[0.35 - 128.75]Shinkai M, 2022 RNA based vaccine BNT162b2 Boost S-268019-b Boost BNT162b2 NR Adults 0 / 101 0 / 103 NR Bruminhent J, 2022 Inactivated virus 2 doses of CoronaVac (3–5 weeks apart) or followed by 1 dose of ChAdOx1 or 2 doses of ChAdOx1 CoronaVac or ChAdOx1/Boost BNT162b2 or mRNA-1273 Boost ChAdOx1 0.2 Kidney transplant recipients 0 / 40 0 / 37 NR Rose W, 2023 Non replicating viral vector ChAdOx1 Boost BBV152 Boost ChAdOx1 3 Adults 0 / 99 2 / 101 0.2
[0.01 - 4.2]Rose W, 2023 Inactivated virus BBV152 Boost ChAdOx1 Boost BBV152 3 Adults 1 / 102 1 / 102 1
[0.06 - 15.77]Assantachai P, 2023 Non replicating viral vector ChAdOx1 Boost mRNA-1273 20 mcg ID Boost mRNA-1273 3 Adults 0 / 35 0 / 35 NR Assantachai P, 2023 Non replicating viral vector ChAdOx1 Boost BNT162b2 10 mcg ID Boost BNT162b2 3 Adults 0 / 70 0 / 70 NR Corominas J, 2023 RNA based vaccine BNT162b2 Boost PHH-1V Boost BNT162b2 3.2 Healthy adults 1 / 513 0 / 252 1.48
[0.06 - 36.09]Jin L, 2022 Inactivated virus CoronaVac Boost Ad5-vectored high dose Boost CoronaVac 12 Healthy adults 1 / 137 1 / 137 1
[0.06 - 15.83]Jin L, 2022 Inactivated virus CoronaVac Boost Ad5-vectored low dose Boost CoronaVac 6 Healthy adults 2 / 139 1 / 137 1.97
[0.18 - 21.49]Kho M, 2022 RNA based vaccine mRNA-1273 or BNT162b2 Boost mRNA-1273 (2 doses) Boost mRNA-1273 0.9 Adult kidney transplant recipients 0 / 75 3 / 71 0.14
[0.01 - 2.57]Kho M, 2022 RNA based vaccine mRNA-1273 or BNT162b2 Boost Ad26.COV2-S Boost mRNA-1273 0.9 Adult kidney transplant recipients 1 / 78 3 / 71 0.3
[0.03 - 2.85]Wang L, 2022 Inactivated virus CoronaVac Boost CoronaVac 1.5 10m Boost CoronaVax 1.5 12m 1 Children and adolescents 1 / 86 0 / 87 3.03
[0.13 - 73.46]Wang L, 2022 Inactivated virus CoronaVac Boost CoronaVax 3 10m Boost CoronaVax 3 12m 1 Children and adolescents 0 / 85 0 / 88 NR Sablerolles R, 2022 Non replicating viral vector Ad26.COV2.S Boost m-RNA-1273 Boost Ad26.COV2.S 1 Healthcare workers 0 / 112 0 / 106 NR Sablerolles R, 2022 Non replicating viral vector Ad26.COV2.S Boost BNT162b2 Boost Ad26.COV2.S 1 Healthcare workers 0 / 111 0 / 106 NR Costa Clemens, 2022 Non replicating viral vector ChadOx1 Boost 9 mcg SCB-2019 + alum Boost ChadOx1 0.92 Adults 0 / 30 0 / 29 NR Costa Clemens, 2022 Non replicating viral vector ChadOx1 Boost 9 mcg SCB-2019 + CpG + alum Boost ChadOx1 0.92 Adults 1 / 29 0 / 29 3
[0.13 - 70.59]Costa Clemens, 2022 Non replicating viral vector ChadOx1 Boost 30 mcg SCB-2019 + CpG + alum Boost ChadOx1 0.92 Adults 0 / 32 0 / 29 NR Natori Y, 2023 RNA based vaccine BNT162b2 Boost Ad26.COV2.S Boost BNT162b2 1 Transplant recipients 0 / 28 0 / 30 NR Jin P, 2023 a Inactivated virus CoronaVac Boost Ad5-vectored 5×10^10 vp Boost CoronaVac 6 Elderly 1 / 99 0 / 100 3.03
[0.12 - 73.49]Intapiboon P, 2021 Inactivated virus CoronaVac CoronaVac 3mcg D0/14 CoronaVac 1 Healthy adults 0 / 30 0 / 30 NR Intapiboon P, 2021 Inactivated virus CoronaVac CoronaVac 3mcg D0/14 CoronaVac 1 Healthy adults 0 / 31 0 / 30 NR Akahata W, 2023 a RNA based vaccine BNT162b2 Boost VLPCOV-01 0.3 mcg Boost BNT162b2 6 Healthy volunteers 0 / 10 0 / 10 NR Akahata W, 2023 a RNA based vaccine BNT162b2 Boost VLPCOV-01 1 mcg Boost BNT162b2 6 Healthy volunteers 0 / 10 0 / 10 NR Akahata W, 2023 a RNA based vaccine BNT162b2 Boost VLPCOV-01 3 mcg Boost BNT162b2 6 Healthy volunteers 0 / 10 0 / 10 NR Akahata W , 2023 b RNA based vaccine BNT162b2 Boost VLPCOV-01 0.3 mcg Boost BNT162b2 6 Healthy volunteers 0 / 10 0 / 10 NR Akahata W , 2023 b RNA based vaccine BNT162b2 Boost VLPCOV-01 1 mcg Boost BNT162b2 6 Healthy volunteers 0 / 10 0 / 10 NR Akahata W , 2023 b RNA based vaccine BNT162b2 Boost VLPCOV-01 3 mcg Boost BNT162b2 6 Healthy volunteers 0 / 10 0 / 10 NR
All-cause mortality
r1: Number of events in intervention 1, r2: Number of events in intervention 2, N1: Number of patients analyzed in intervention 1; N2: Number of patients analyzed in intervention 2.Reference Type of prime vaccination Prime schedule Intervention 1 Intervention 2 Follow up
monthsParticipants r1/N1 r2/N2 RR [95% CI] Risk of bias A B C D E Overall Corominas J, 2023 RNA based vaccine BNT162b2 Boost PHH-1V Boost BNT162b2 3.2 Healthy adults 0 / 513 0 / 252 NR Zhang Y, 2023 Inactivated virus CoronaVac Boost ChAdTS-S Placebo 3 Adults 0 / 48 0 / 47 NR Zhang Y, 2023 Inactivated virus CoronaVac Boost RQ3013 Placebo 3 Adults 0 / 47 0 / 47 NR Zhang Y, 2023 Inactivated virus CoronaVac Boost ZR202-CoV Placebo 3 Adults 0 / 47 0 / 47 NR Zhang Y, 2023 Inactivated virus CoronaVac Boost CoronaVac Placebo 3 Adults 0 / 46 0 / 47 NR Mrak D, 2022 RNA based vaccine mRNA-1273 or BNT162b2 Boost ChAdOx1 Boost homologous mRNA-1273 or BNT162b2 0.9 Immunosuppressed adults 0 / 22 0 / 24 NR Al Kaabi N, 2022 b Inactivated virus BBIBP-CorV Boost NVSI-06-08 4-6 months Boost BBIBP-CorV 4-6 months 1 Healthy adults 0 / 299 0 / 301 NR Al Kaabi N, 2022 b Inactivated virus BBIBP-CorV Boost NVSI-06-08 7-9 months Boost BBIBP-CorV 7-9 months 1 Healthy adults 0 / 297 0 / 303 NR Al Kaabi N, 2022 b Inactivated virus BBIBP-CorV Boost NVSI-06-08 >9 months Boost BBIBP-CorV >9 months 1 Healthy adults 0 / 300 0 / 300 NR Lien C, 2022 a Protein subunit MVC-COV1901 Boost MVC-COV1901-Beta 15 mcg Boost MVC-COV1901 0.9 Adults including healthy or stable co-morbidities 0 / 15 0 / 15 NR Lien C, 2022 a Protein subunit MVC-COV1901 Boost MVC-COV1901-Beta 25 mcg Boost MVC-COV1901 0.9 Adults including healthy or stable co-morbidities 0 / 15 0 / 15 NR Amplify, 2023 a Non replicating viral vector Ad26.COV2.S Boost Ad26.COV2.S 1*10^10 vp Boost Ad26.COV2.S 5*10^10 vp 4.5 Adults including elderly and stable co-morbidities 0 / 116 0 / 330 NR Amplify, 2023 a Non replicating viral vector Ad26.COV2.S Boost Ad26.COV2.S 2.5*10^10 vp Boost Ad26.COV2.S 5*10^10 vp 4.5 Adults including elderly and stable co-morbidities 0 / 328 0 / 330 NR Amplify, 2023 b RNA based vaccine BNT162b2 Boost Ad26.COV2.S 1*10^10 vp Boost Ad26.COV2.S 5*10^10 vp 4.5 Adults including elderly and stable co-morbidities 0 / 106 0 / 326 NR Amplify, 2023 b RNA based vaccine BNT162b2 Boost Ad26.COV2.S 2.5*10^10 vp Boost Ad26.COV2.S 5*10^10 vp 4.5 Adults including elderly and stable co-morbidities 0 / 326 0 / 326 NR Rose W, 2023 Non replicating viral vector ChAdOx1 Boost BBV152 Boost ChAdOx1 3.0 Adults 0 / 99 0 / 101 NR Rose W, 2023 Inactivated virus BBV152 Boost ChAdOx1 Boost BBV152 3.0 Adults 0 / 102 0 / 102 NR Rao C, 2022 Inactivated virus CoronaVac Boost SCB-2019 Boost CoronaVac 2.0 Adults who are healthy or have a stable pre-existing medical condition 0 / 214 0 / 216 NR Tawinprai K, 2022 Inactivated virus CoronaVac Boost ChAdOx1 Boost BBIBP-CorV 0.5 Adults without active underlying disease 0 / 41 0 / 40 NR Chuang C-H, 2022 Non replicating viral vector ChAdOx1 Boost BNT162b2 Boost MVC-COV1901 5.9 Healthcare workers 0 / 83 0 / 85 NR Chuang C-H, 2022 Non replicating viral vector ChAdOx1 Boost mRNA-1273 (half dose) Boost MVC-COV1901 5.9 Healthcare workers 0 / 85 0 / 85 NR Chuang C-H, 2022 Non replicating viral vector ChAdOx1 Boost mRNA-1273 Boost MVC-COV1901 5.9 Healthcare workers 0 / 85 0 / 85 NR Reindl-Schwaighofer R, 2021 RNA based vaccine BNT162b2 or mRNA-1273 Boost BNT162b2 or mRNA-1273 Boost Ad26COVS1 3 Kidney transplant recipients 4 / 99 4 / 99 1
[0.26 - 3.88]Shinkai M, 2022 RNA based vaccine BNT162b2 Boost S-268019-b Boost BNT162b2 * Adults 0 / 101 0 / 103 NR Costa Clemens, 2022 Non replicating viral vector ChadOx1 Boost 9 mcg SCB-2019 + alum Boost ChadOx1 2.53 Adults 0 / 30 0 / 29 NR Costa Clemens, 2022 Non replicating viral vector ChadOx1 Boost 9 mcg SCB-2019 + CpG + alum Boost ChadOx1 2.53 Adults 0 / 29 0 / 29 NR Costa Clemens, 2022 Non replicating viral vector ChadOx1 Boost 30 mcg SCB-2019 + CpG + alum Boost ChadOx1 2.53 Adults 0 / 32 0 / 29 NR Toledo-Romani ME, 2022 a Protein subunit FINLAY-FR-2-25 mcg Boost FR-1 Boost FINLAY-FR-2 1 Healthy adults 0 / 58 0 / 55 NR Estephan L, 2023 a Protein subunit MVC-COV1901 Boost 1/2 MVC-COV1901 Boost MVC-COV1901 5.16 Adults 0 / 78 0 / 78 NR Estephan L, 2023 a Protein subunit MVC-COV1901 Boost 1/2 mRNA-1273 Boost MVC-COV1901 5.16 Adults 0 / 77 0 / 78 NR Estephan L, 2023 a Protein subunit MVC-COV1901 Boost ChAdOx1 Boost MVC-COV1901 5.16 Adults 0 / 80 0 / 78 NR Estephan L, 2023 c RNA based vaccine mRNA-1273 Boost MVC-COV1901 Boost 1/2 mRNA-1273 5.16 Adults 0 / 35 0 / 44 NR Estephan L, 2023 c RNA based vaccine mRNA-1273 Boost ChAdOx1 Boost 1/2 mRNA-1273 5.16 Adults 0 / 42 0 / 44 NR Estephan L, 2023 c RNA based vaccine mRNA-1273 Boost 1/2 MVC-COV1901 Boost 1/2 mRNA-1273 5.16 Adults 0 / 42 0 / 44 NR Estephan L, 2023 b Non replicating viral vector ChadOx1 Boost MVC-COV1901 Boost ChadOx1 5.16 Adults 0 / 79 0 / 81 NR Estephan L, 2023 b Non replicating viral vector ChadOx1 Boost mRNA-1273 (half dose) Boost ChadOx1 5.16 Adults 0 / 82 0 / 81 NR Natori Y, 2023 RNA based vaccine BNT162b2 Boost Ad26.COV2.S Boost BNT162b2 6 Transplant recipients 0 / 28 0 / 30 NR
- Immunogenicity
Second Boost
- 2nd booster VS 1st booster (tables)
No data
- 2nd booster VS 2nd booster (tables)
- Immunogenicity
Geometric mean titre specific antibodies (D14)
Number of patients analyzed in intervention 1; N2: Number of patients analyzed in intervention 2; GMT1: Geometric mean titre for intervention 1; GMT2: Geometric mean titre for intervention 2; N1GMR: Geometric mean ratioReference Type of prime vaccination Prime schedule Intervention 1 Intervention 2 Follow up
daysParticipants GMT1(N1) GMT2(N2) GMR [95% CI] Evaluated by Risk of bias A B C D E Overall Lien C, 2022 b Protein subunit MVC-COV1901 Boost MVC-COV1901+boost MVC-COV1901-Beta 15 mcg Boost MVC-COV1901+boost MVC-COV1901 14 Adults including healthy or stable co-morbidities 28,179
(19)21,078
(18)1.33 [0.88, 2.01] ELISA Lien C, 2022 b Protein subunit MVC-COV1901 Boost MVC-COV1901+boost MVC-COV1901-Beta 25 mcg Boost MVC-COV1901+boost MVC-COV1901 14 Adults including healthy or stable co-morbidities 21,638
(18)21,078
(18)1.02 [0.67, 1.55] ELISA Barda N, 2023 RNA based vaccine BNT162b2 Boost BNT161b2-OMI 30mcg Boost BNT162b2 30 Adults 4,774
(19)5,409
(20)0.88 [0.53, 1.48] Automatic chemiluminescent microparticle immunoassay Barda N, 2023 RNA based vaccine BNT162b2 Boost BNT161b2-OMI 60mcg Boost BNT162b2 30 Adults 5,959
(19)5,409
(20)1.10 [0.73, 1.65] Automatic chemiluminescent microparticle immunoassay Barda N, 2023 RNA based vaccine BNT162b2 Boost BNT161b2-OMI 15/15mcg Boost BNT162b2 30 Adults 7,487
(19)5,409
(20)1.38 [0.81, 2.37] Automatic chemiluminescent microparticle immunoassay Barda N, 2023 RNA based vaccine BNT162b2 Boost BNT161b2-OMI 30/30mcg Boost BNT162b2 30 Adults 4,672
(21)5,409
(20)0.86 [0.56, 1.33] Automatic chemiluminescent microparticle immunoassay Barda N, 2023 RNA based vaccine BNT162b2 Boost BNT162b2 60mcg Boost BNT162b2 30 Adults 3,611
(19)5,409
(20)0.67 [0.40, 1.11] Automatic chemiluminescent microparticle immunoassay Toback S, 2023 Inactivated virus BBIBP-CorV Boost NVX-CoV2373 Boost BBIBP-CorV 14 Healthy volunteers 388
(479)215
(486)1.8 [1.7, 1.9] Chemiluminescence immunoassay (CLIA)
Geometric mean titre specific antibodies (≥D90)
Number of patients analyzed in intervention 1; N2: Number of patients analyzed in intervention 2; GMT1: Geometric mean titre for intervention 1; GMT2: Geometric mean titre for intervention 2; N1GMR: Geometric mean ratioReference Type of prime vaccination Prime schedule Intervention 1 Intervention 2 Follow up
daysParticipants GMT1(N1) GMT2(N2) GMR [95% CI] Evaluated by Risk of bias A B C D E Overall Barda N, 2023 RNA based vaccine BNT162b2 Boost BNT161b2-OMI 30mcg Boost BNT162b2 90 Adults 4,304
(14)2,981
(16)1.44 [0.71, 2.92] Automatic chemiluminescent microparticle immunoassay Barda N, 2023 RNA based vaccine BNT162b2 Boost BNT161b2-OMI 60mcg Boost BNT162b2 90 Adults 3,901
(14)2,981
(16)1.31 [0.73, 2.33] Automatic chemiluminescent microparticle immunoassay Barda N, 2023 RNA based vaccine BNT162b2 Boost BNT161b2-OMI 15/15mcg Boost BNT162b2 90 Adults 4,605
(17)2,981
(16)1.54 [0.78, 3.05] Automatic chemiluminescent microparticle immunoassay Barda N, 2023 RNA based vaccine BNT162b2 Boost BNT161b2-OMI 30/30mcg Boost BNT162b2 90 Adults 3,001
(19)2,981
(16)1.01 [0.57, 1.78] Automatic chemiluminescent microparticle immunoassay Barda N, 2023 RNA based vaccine BNT162b2 Boost BNT162b2 60mcg Boost BNT162b2 90 Adults 2,314
(16)2,981
(16)0.78 [0.43, 1.39] Automatic chemiluminescent microparticle immunoassay
Geometric mean titre neutralization assay against wild type (D14)
Number of patients analyzed in intervention 1; N2: Number of patients analyzed in intervention 2; GMT1: Geometric mean titre for intervention 1; GMT2: Geometric mean titre for intervention 2; N1GMR: Geometric mean ratioReference Type of prime vaccination Prime schedule Intervention 1 Intervention 2 Follow up
daysParticipants GMT1(N1) GMT2(N2) GMR [95% CI] Evaluated by Risk of bias A B C D E Overall Lien C, 2022 b Protein subunit MVC-COV1901 Boost MVC-COV1901+boost MVC-COV1901-Beta 15 mcg Boost MVC-COV1901+boost MVC-COV1901 28 Adults including healthy or stable co-morbidities 1,125
(19)868
(18)1.29 [0.82, 2.02] Plaque reduction neutralization test Lien C, 2022 b Protein subunit MVC-COV1901 Boost MVC-COV1901+boost MVC-COV1901-Beta 25 mcg Boost MVC-COV1901+boost MVC-COV1901 28 Adults including healthy or stable co-morbidities 929
(18)868
(18)1.06 [0.68, 1.67] Plaque reduction neutralization test Branche A, 2023 Any COVID-19 vaccine BNT162b2 OR mRNA-1273 OR Ad26.COV2.S 2nd Boost BNT162b2 Omicron BA.1 2nd Boost BNT162b2 Omicron BA.4/5 14 Adults including healthy or stable co-morbidities 27,000
(98)34,109
(98)0.79 [0.64, 0.97] Pseudovirus Neutralization Assay Branche A, 2022 a Any COVID-19 vaccine Completed primary and booster COVID-19 vaccine series, either homologous or heterologous Boost mRNA Omicron + Beta vaccine Boost Original mRNA-1273 vaccine 15 Adults 19,760
(198)20,969
(97)0.94 [0.73, 1.22] Pseudovirion-based neutralisation assay Branche A, 2022 a Any COVID-19 vaccine Completed primary and booster COVID-19 vaccine series, either homologous or heterologous Boost mRNA Omicron + Delta vaccine Boost Original mRNA-1273 vaccine 15 Adults 24,337
(99)20,969
(97)1.16 [0.85, 1.59] Pseudovirion-based neutralisation assay Branche A, 2022 a Any COVID-19 vaccine Completed primary and booster COVID-19 vaccine series, either homologous or heterologous Boost mRNA Omicron + Original mRNA-1273 vaccine Boost Original mRNA-1273 vaccine 15 Adults 26,125
(96)20,969
(97)1.25 [0.95, 1.64] Pseudovirion-based neutralisation assay Branche A, 2022 a Any COVID-19 vaccine Completed primary and booster COVID-19 vaccine series, either homologous or heterologous Boost mRNA Omicron vaccine Boost Original mRNA-1273 vaccine 15 Adults 19,167
(96)20,969
(97)0.91 [0.70, 1.20] Pseudovirion-based neutralisation assay He Q, 2022 b Inactivated virus CoronaVac or BBIBP-CorV Boost BV-01-B5 Boost BV-01-B5 14 Healthy adults 1,327
(24)1,327
(24)2.06 [0.92, 4.59] Pseudovirus neutralization assay Barda N, 2023 RNA based vaccine BNT162b2 Boost BNT161b2-OMI 30mcg Boost BNT162b2 30 Adults 3,010
(18)4,390
(20)0.68 [0.32, 1.47] Live Micro-neutralization assay Barda N, 2023 RNA based vaccine BNT162b2 Boost BNT161b2-OMI 60mcg Boost BNT162b2 30 Adults 3,808
(19)4,390
(20)0.87 [0.42, 1.79] Live Micro-neutralization assay Barda N, 2023 RNA based vaccine BNT162b2 Boost BNT161b2-OMI 15/15mcg Boost BNT162b2 30 Adults 5,288
(19)4,390
(20)1.20 [0.63, 2.29] Live Micro-neutralization assay Barda N, 2023 RNA based vaccine BNT162b2 Boost BNT161b2-OMI 30/30mcg Boost BNT162b2 30 Adults 2,521
(20)4,390
(20)0.57 [0.28, 1.18] Live Micro-neutralization assay Barda N, 2023 RNA based vaccine BNT162b2 Boost BNT162b2 60mcg Boost BNT162b2 30 Adults 2,048
(18)4,390
(20)0.47 [0.21, 1.06] Live Micro-neutralization assay Winokur P, 2023 RNA based vaccine BNT162b2 Boost biv BNT162b2 OMI 15/15mcg Boost BNT162b2 30 Adults 6,945
(216)7,377
(221)0.94 [0.78, 1.04] Recombinant SARS-CoV-2 neutralization assay Winokur P, 2023 RNA based vaccine BNT162b2 Boost BNT162b2 OMI 60mcg Boost BNT162b2 30 Adults 8,447
(218)7,377
(221)1.14 [0.93, 1.40] Recombinant SARS-CoV-2 neutralization assay Winokur P, 2023 RNA based vaccine BNT162b2 Boost biv BNT162b2 OMI 30/30mcg Boost BNT162b2 30 Adults 9,355
(216)7,377
(221)1.27 [1.04, 1.54] Recombinant SARS-CoV-2 neutralization assay Winokur P, 2023 RNA based vaccine BNT162b2 Boost BNT162b2 OMI 30mcg Boost BNT162b2 30 Adults 6,815
(222)7,377
(221)0.92 [0.75, 1.13] Recombinant SARS-CoV-2 neutralization assay Winokur P, 2023 RNA based vaccine BNT162b2 Boost BNT162b2 60mcg Boost BNT162b2 30 Adults 8,244
(220)7,377
(221)1.11 [0.92, 1.34] Recombinant SARS-CoV-2 neutralization assay Tang R, 2023 Inactivated virus Coronavac Boost Coronovac/BoostAd5-nCoV IN Boost Coronovac/boost Coronavac 14 Healthy adults 292
(117)78
(116)3.7 [2.6, 5.1] Cytopathic effect-based microneutralization assay Tang R, 2023 Inactivated virus Coronavac Boost Coronovac/Ad5-nCoV INCoV IM Boost Coronovac/boost Coronavac 14 Healthy adults 746
(118)78
(116)9.5 [7.3, 12.3] Cytopathic effect-based microneutralization assay He Q, 2022 a Protein subunit CoronaVac or BBIBP-CorV Boost V-01D-351 Boost CoronaVac 14 Healthy adults 5,609
(11)501
(9)11.20 [6.49, 19.30] Pseudovirus neutralization assay Toback S, 2023 Inactivated virus BBIBP-CorV Boost NVX-CoV2373 Boost BBIBP-CorV 14 Healthy volunteers 3,185
(479)559
(486)5.7 [5.1, 6.4] Plaque Reduction Neutralization Test (PRNT)
Geometric mean titre neutralization assay against wild type (≥D90)
Number of patients analyzed in intervention 1; N2: Number of patients analyzed in intervention 2; GMT1: Geometric mean titre for intervention 1; GMT2: Geometric mean titre for intervention 2; N1GMR: Geometric mean ratioReference Type of prime vaccination Prime schedule Intervention 1 Intervention 2 Follow up
daysParticipants GMT1(N1) GMT2(N2) GMR [95% CI] Evaluated by Risk of bias A B C D E Overall Barda N, 2023 RNA based vaccine BNT162b2 Boost BNT161b2-OMI 30mcg Boost BNT162b2 90 Adults 1,765
(14)2,246
(15)0.78 [0.27, 2.28] Live Micro-neutralization assay Barda N, 2023 RNA based vaccine BNT162b2 Boost BNT161b2-OMI 60mcg Boost BNT162b2 90 Adults 1,949
(14)2,246
(15)0.87 [0.35, 2.15] Live Micro-neutralization assay Barda N, 2023 RNA based vaccine BNT162b2 Boost BNT161b2-OMI 15/15mcg Boost BNT162b2 90 Adults 2,315
(17)2,246
(15)1.03 [0.45, 2.37] Live Micro-neutralization assay Barda N, 2023 RNA based vaccine BNT162b2 Boost BNT161b2-OMI 30/30mcg Boost BNT162b2 90 Adults 1,256
(17)2,246
(15)0.56 [0.25, 1.27] Live Micro-neutralization assay Barda N, 2023 RNA based vaccine BNT162b2 Boost BNT162b2 60mcg Boost BNT162b2 90 Adults 1,166
(16)2,246
(15)0.52 [0.22, 1.19] Live Micro-neutralization assay
Geometric mean titre neutralization assay against Omicron variant (D14)
Number of patients analyzed in intervention 1; N2: Number of patients analyzed in intervention 2; GMT1: Geometric mean titre for intervention 1; GMT2: Geometric mean titre for intervention 2; N1GMR: Geometric mean ratioReference Type of prime vaccination Prime schedule Intervention 1 Intervention 2 Follow up
daysParticipants GMT1(N1) GMT2(N2) GMR [95% CI] Evaluated by Risk of bias A B C D E Overall Lien C, 2022 b Protein subunit MVC-COV1901 Boost MVC-COV1901+boost MVC-COV1901-Beta 15 mcg Boost MVC-COV1901+boost MVC-COV1901 28 Adults including healthy or stable co-morbidities 222
(19)137
(18)1.62 [0.86, 3.05] Pseudovirus neutralisation assay Lien C, 2022 b Protein subunit MVC-COV1901 Boost MVC-COV1901+boost MVC-COV1901-Beta 25 mcg Boost MVC-COV1901+boost MVC-COV1901 28 Adults including healthy or stable co-morbidities 155
(18)137
(18)1.13 [0.67, 1.89] Pseudovirus neutralisation assay Branche A, 2023 Any COVID-19 vaccine BNT162b2 OR mRNA-1273 OR Ad26.COV2.S 2nd Boost BNT162b2 Omicron BA.1 2nd Boost BNT162b2 Omicron BA.4/5 14 Adults including healthy or stable co-morbidities 3,546
(98)5,939
(98)0.60 [0.43, 0.83] Pseudovirus neutralization assay Branche A, 2022 a Any COVID-19 vaccine Completed primary and booster COVID-19 vaccine series, either homologous or heterologous Boost mRNA Omicron + Beta vaccine Boost Original mRNA-1273 vaccine 15 Adults 4,784
(198)2,699
(97)1.77 [1.24, 2.53] Pseudotyped lentiviruses Branche A, 2022 a Any COVID-19 vaccine Completed primary and booster COVID-19 vaccine series, either homologous or heterologous Boost mRNA Omicron + Delta vaccine Boost Original mRNA-1273 vaccine 15 Adults 4,503
(99)2,699
(97)1.67 [1.09, 2.54] Pseudotyped lentiviruses Branche A, 2022 a Any COVID-19 vaccine Completed primary and booster COVID-19 vaccine series, either homologous or heterologous Boost mRNA Omicron + Original mRNA-1273 vaccine Boost Original mRNA-1273 vaccine 15 Adults 5,322
(96)2,699
(97)1.97 [1.31, 2.95] Pseudotyped lentiviruses Branche A, 2022 a Any COVID-19 vaccine Completed primary and booster COVID-19 vaccine series, either homologous or heterologous Boost mRNA Omicron vaccine Boost Original mRNA-1273 vaccine 15 Adults 6,011
(96)2,699
(97)2.23 [1.52, 3.26] Pseudotyped lentiviruses He Q, 2022 b Inactivated virus CoronaVac or BBIBP-CorV Boost BV-01-B5 Boost BV-01-B5 14 Healthy adults 500
(24)500
(24)3.68 [1.15, 11.77] Pseudovirus neutralization assay Barda N, 2023 RNA based vaccine BNT162b2 Boost BNT161b2-OMI 30mcg Boost BNT162b2 30 Adults 575
(18)402
(20)1.43 [0.67, 3.06] Live Micro-neutralization assay Barda N, 2023 RNA based vaccine BNT162b2 Boost BNT161b2-OMI 60mcg Boost BNT162b2 30 Adults 765
(19)402
(20)1.90 [0.82, 4.44] Live Micro-neutralization assay Barda N, 2023 RNA based vaccine BNT162b2 Boost BNT161b2-OMI 15/15mcg Boost BNT162b2 30 Adults 1,062
(19)402
(20)2.64 [1.07, 6.53] Live Micro-neutralization assay Barda N, 2023 RNA based vaccine BNT162b2 Boost BNT161b2-OMI 30/30mcg Boost BNT162b2 30 Adults 478
(20)402
(20)1.19 [0.50, 2.87] Live Micro-neutralization assay Barda N, 2023 RNA based vaccine BNT162b2 Boost BNT162b2 60mcg Boost BNT162b2 30 Adults 188
(18)402
(20)0.47 [1.19, 1.17] Live Micro-neutralization assay Winokur P, 2023 RNA based vaccine BNT162b2 Boost biv BNT162b2 OMI 15/15mcg Boost BNT162b2 30 Adults 884
(216)663
(221)1.33 [0.99, 1.78] Recombinant SARS-CoV-2 neutralization assay Winokur P, 2023 RNA based vaccine BNT162b2 Boost BNT162b2 OMI 60mcg Boost BNT162b2 30 Adults 1,836
(218)663
(221)2.76 [2.08, 3.67] Recombinant SARS-CoV-2 neutralization assay Winokur P, 2023 RNA based vaccine BNT162b2 Boost biv BNT162b2 OMI 30/30mcg Boost BNT162b2 30 Adults 1,140
(216)663
(221)1.71 [1.27, 2.32] Recombinant SARS-CoV-2 neutralization assay Winokur P, 2023 RNA based vaccine BNT162b2 Boost BNT162b2 OMI 30mcg Boost BNT162b2 30 Adults 1,346
(222)663
(221)2.03 [1.51, 2.72] Recombinant SARS-CoV-2 neutralization assay Winokur P, 2023 RNA based vaccine BNT162b2 Boost BNT162b2 60mcg Boost BNT162b2 30 Adults 821
(220)663
(221)1.23 [0.92, 1.65] Recombinant SARS-CoV-2 neutralization assay Tang R, 2023 Inactivated virus Coronavac Boost Coronovac/BoostAd5-nCoV IN Boost Coronovac/boost Coronavac 14 Healthy adults 63
(117)21
(116)3.0 [2.3, 3.8] Pseudovirus neutralisation tests Tang R, 2023 Inactivated virus Coronavac Boost Coronovac/Ad5-nCoV INCoV IM Boost Coronovac/boost Coronavac 14 Healthy adults 117
(118)21
(116)5.6 [4.6, 7.3] Pseudovirus neutralisation tests He Q, 2022 a Protein subunit CoronaVac or BBIBP-CorV Boost V-01D-351 Boost CoronaVac 14 Healthy adults 192
(11)16
(9)12 [3.33, 43.19] Pseudovirus neutralization assay
Geometric mean titre neutralization assay against Omicron variant (≥D90)
Number of patients analyzed in intervention 1; N2: Number of patients analyzed in intervention 2; GMT1: Geometric mean titre for intervention 1; GMT2: Geometric mean titre for intervention 2; N1GMR: Geometric mean ratioReference Type of prime vaccination Prime schedule Intervention 1 Intervention 2 Follow up
daysParticipants GMT1(N1) GMT2(N2) GMR [95% CI] Evaluated by Risk of bias A B C D E Overall Barda N, 2023 RNA based vaccine BNT162b2 Boost BNT161b2-OMI 30mcg Boost BNT162b2 90 Adults 328
(14)154
(15)2.12 [0.57, 7.87] Live Micro-neutralization assay Barda N, 2023 RNA based vaccine BNT162b2 Boost BNT161b2-OMI 60mcg Boost BNT162b2 90 Adults 512
(14)154
(15)3.32 [1.25, 8.83] Live Micro-neutralization assay Barda N, 2023 RNA based vaccine BNT162b2 Boost BNT161b2-OMI 15/15mcg Boost BNT162b2 90 Adults 435
(17)154
(15)2.82 [0.93, 8.49] Live Micro-neutralization assay Barda N, 2023 RNA based vaccine BNT162b2 Boost BNT161b2-OMI 30/30mcg Boost BNT162b2 90 Adults 246
(17)154
(15)1.60 [0.53, 4.79] Live Micro-neutralization assay Barda N, 2023 RNA based vaccine BNT162b2 Boost BNT162b2 60mcg Boost BNT162b2 90 Adults 95
(16)154
(15)0.61 [0.22, 1.72] Live Micro-neutralization assay - Safety
Serious adverse events
r1: Number of events in intervention 1, r2: Number of events in intervention 2, N1: Number of patients analyzed in intervention 1; N2: Number of patients analyzed in intervention 2.Reference Type of prime vaccination Prime schedule Intervention 1 Intervention 2 Follow up
monthsParticipants r1/N1 r2/N2 RR [95% CI] Risk of bias A B C D E Overall Lien C, 2022 b Protein subunit MVC-COV1901 Boost MVC-COV1901+boost MVC-COV1901-Beta 15 mcg Boost MVC-COV1901+boost MVC-COV1901 0.9 Adults including healthy or stable co-morbidities 0 / 21 0 / 21 NR Lien C, 2022 b Protein subunit MVC-COV1901 Boost MVC-COV1901+boost MVC-COV1901-Beta 25 mcg Boost MVC-COV1901+boost MVC-COV1901 0.9 Adults including healthy or stable co-morbidities 0 / 20 0 / 21 NR Lee I, 2023 a Any COVID-19 vaccine Any authorized COVID Boost mRNA-1273.529 Boost mRNA-1273 1 Aged at least 16 years including healthy, elderly and/or stable co-morbidities 5 / 367 1 / 357 4.86
[0.57 - 41.43]Lee l, 2023 b Any COVID-19 vaccine Any authorized COVID-19 vaccine of: BNT162b2, mRNA-1273, ChAdOx1, Ad26.COV2.S Boost mRNA-1273.214 Boost mRNA-1273 1 Aged at least 16 years including healthy, elderly and/or stable co-morbidities 6 / 1422 5 / 1402 1.18
[0.36 - 3.87]Branche A, 2023 Any COVID-19 vaccine BNT162b2 OR mRNA-1273 OR Ad26.COV2.S 2nd Boost BNT162b2 Omicron BA.1 2nd Boost BNT162b2 Omicron BA.4/5 29 Adults including healthy or stable co-morbidities 0 / 101 0 / 101 NR He Q, 2022 b Inactivated virus CoronaVac or BBIBP-CorV Boost BV-01-B5 Boost BV-01-B5 1 Healthy adults 0 / 24 0 / 24 NR Winokur P, 2023 RNA based vaccine BNT162b2 Boost biv BNT162b2 OMI 15/15mcg Boost BNT162b2 1.7 Adults 1 / 305 2 / 305 0.5
[0.05 - 5.49]Winokur P, 2023 RNA based vaccine BNT162b2 Boost BNT162b2 OMI 60mcg Boost BNT162b2 1.7 Adults 0 / 306 2 / 305 0.2
[0.01 - 4.14]Winokur P, 2023 RNA based vaccine BNT162b2 Boost biv BNT162b2 OMI 30/30mcg Boost BNT162b2 1.7 Adults 2 / 316 2 / 305 0.97
[0.14 - 6.81]Winokur P, 2023 RNA based vaccine BNT162b2 Boost BNT162b2 OMI 30mcg Boost BNT162b2 1.7 Adults 3 / 307 2 / 305 1.49
[0.25 - 8.86]Winokur P, 2023 RNA based vaccine BNT162b2 Boost BNT162b2 60mcg Boost BNT162b2 1.7 Adults 0 / 302 2 / 305 0.2
[0.01 - 4.19]Munro APS, 2022 RNA based vaccine BNT162b2 + boost BNT162b2 Boost BNT162b2 Boost half dose m-RNA 1273 1.7 Healthy adults 1 / 39 0 / 39 3
[0.13 - 71.37]Munro APS, 2022 Non replicating viral vector ChadOx1 + boost BNT162b2 Boost BNT162b2 Boost half dose m-RNA 1273 1.7 Healthy adults 2 / 44 0 / 44 5
[0.25 - 101.12]Tang R, 2023 Inactivated virus Coronavac Boost Coronovac/BoostAd5-nCoV IN Boost Coronovac/boost Coronavac 0.9 Healthy adults 0 / 117 0 / 119 NR Tang R, 2023 Inactivated virus Coronavac Boost Coronovac/Ad5-nCoV INCoV IM Boost Coronovac/boost Coronavac 0.9 Healthy adults 0 / 120 0 / 119 NR He Q, 2022 a Protein subunit CoronaVac or BBIBP-CorV Boost V-01D-351 Boost CoronaVac 0.9 Healthy adults 0 / 11 0 / 9 NR Toback S, 2023 Inactivated virus BBIBP-CorV Boost NVX-CoV2373 Boost BBIBP-CorV 1 Healthy volunteers 0 / 497 0 / 501 NR
All-cause mortality
r1: Number of events in intervention 1, r2: Number of events in intervention 2, N1: Number of patients analyzed in intervention 1; N2: Number of patients analyzed in intervention 2.Reference Type of prime vaccination Prime schedule Intervention 1 Intervention 2 Follow up
monthsParticipants r1/N1 r2/N2 RR [95% CI] Risk of bias A B C D E Overall Tang R, 2023 Inactivated virus Coronavac Boost Coronovac/BoostAd5-nCoV IN Boost Coronovac/boost Coronavac 0.9 Healthy adults 0 / 117 0 / 119 NR Tang R, 2023 Inactivated virus Coronavac Boost Coronovac/Ad5-nCoV INCoV IM Boost Coronovac/boost Coronavac 0.9 Healthy adults 0 / 120 0 / 119 NR Lien C, 2022 b Protein subunit MVC-COV1901 Boost MVC-COV1901+boost MVC-COV1901-Beta 15 mcg Boost MVC-COV1901+boost MVC-COV1901 0.9 Adults including healthy or stable co-morbidities 0 / 21 0 / 21 NR Lien C, 2022 b Protein subunit MVC-COV1901 Boost MVC-COV1901+boost MVC-COV1901-Beta 25 mcg Boost MVC-COV1901+boost MVC-COV1901 0.9 Adults including healthy or stable co-morbidities 0 / 20 0 / 21 NR Lee I, 2023 a Any COVID-19 vaccine Any authorized COVID Boost mRNA-1273.529 Boost mRNA-1273 4.6 Aged at least 16 years including healthy, elderly and/or stable co-morbidities 0 / 367 0 / 357 NR Lee l, 2023 b Any COVID-19 vaccine Any authorized COVID-19 vaccine of: BNT162b2, mRNA-1273, ChAdOx1, Ad26.COV2.S Boost mRNA-1273.214 Boost mRNA-1273 2.9 Aged at least 16 years including healthy, elderly and/or stable co-morbidities 0 / 1422 0 / 1402 NR Winokur P, 2023 RNA based vaccine BNT162b2 Boost biv BNT162b2 OMI 15/15mcg Boost BNT162b2 1.7 Adults 0 / 305 0 / 305 NR Winokur P, 2023 RNA based vaccine BNT162b2 Boost BNT162b2 OMI 60mcg Boost BNT162b2 1.7 Adults 0 / 306 0 / 305 NR Winokur P, 2023 RNA based vaccine BNT162b2 Boost biv BNT162b2 OMI 30/30mcg Boost BNT162b2 1.7 Adults 0 / 316 0 / 305 NR Winokur P, 2023 RNA based vaccine BNT162b2 Boost BNT162b2 OMI 30mcg Boost BNT162b2 1.7 Adults 0 / 307 0 / 305 NR Winokur P, 2023 RNA based vaccine BNT162b2 Boost BNT162b2 60mcg Boost BNT162b2 1.7 Adults 0 / 302 0 / 305 NR
- Immunogenicity
COVID-19 PRIME VACCINATION: Last search date December 14, 2022.
Click here to see Covid-19 prime vaccination studies
Trials reports under extraction
In addition to the below included trials, we have included and presently extracting 12 new vaccine randomized trials
Description of primary studies
In this table, we report the main characteristics of the COVID-19 vaccine candidates from RCTs identified, in addition to the overall risk of bias assessment.
For prime vaccination, early phase trials were extracted only when the dose has been selected. Results from phase 1-2 studies are included in forest plots for the chosen vaccine dose and schedule only. List of early phases included but not extracted are detailed on here .
Search studies
Your research ==> Vaccine name: 1273
| Trial | Type | Comparisons | Design | Participants | Sample size | Overall risk of bias Highest assessment |
Full description | |
|---|---|---|---|---|---|---|---|---|
| Intervention 1 | Intervention 2 | |||||||
|
NCT04649151 ModernaTX Ali K, N Engl J Med, 2021 Full text Commentary |
RNA based vaccine |
mRNA-1273 |
Placebo |
RCTPhase 2-3 | Healthy adolescents in 26 centers in the USA | N= 3732 |
Some concerns Details |
|
|
NCT04796896 Moderna TX Anderson E, N Engl J Med, 2022 b Full text Commentary |
RNA based vaccine |
mRNA-1273 |
Placebo |
RCTPhase 2-3 | Children 6 to 23 months of age, including healthy and those with stable chronic diseases in 87 centres in USA (79 sites) and Canada (8 sites). | N= 2355 |
Some concerns Details |
|
|
NCT04283461; NCT04785144 Moderna + National Institute of Allergy and Infectious Diseases (NIAID) Anderson E, SSRN, 2022 Full text Commentary Commentary |
Homologous booster |
mRNA-1273/Boost 50 mcg of mRNA-1273.351 mRNA-1273/Boost mRNA-1273 |
mRNA-1273/Boost 25 mcg mRNA- 1273.351 and 25 mcg mRNA-1273 |
RCTPhase 1 | Healthy adult volunteers who were SARS-CoV-2 infection-free in 3 sites in the USA | N= 96 |
Some concerns Details |
|
|
NCT04796896 Moderna TX Anderson E, N Engl J Med , 2022 a Full text Commentary |
RNA based vaccine |
mRNA-1273 |
Placebo |
RCTPhase 2-3 | Children 2 to 5 years of age, including healthy and those with stable chronic diseases in 87 centres in USA (79 sites) and Canada (8 sites). | N= 4048 |
Some concerns Details |
|
|
TCTR20220112002 Moderna; Pfizer Assantachai P, J Infect Dis, 2023 Full text Full text Commentary |
RNA based vaccine |
ChAdOx1/Boost mRNA1273-20 mcg ID ChAdOx1/Boost BNT162b2- 10MCG ID |
ChAd/Boost mRNA1273 ChadOx1/boostBNT |
RCT4 | Adults 65 years of age or older in a single centre in Thailand | N= 210 |
Some concerns Details |
|
|
EudraCT 2021-002348-57 Pfizer-BioNTech; Moderna; Oxford-AstraZeneca Bonelli M, Ann Rheum Dis , 2022 Full text Commentary |
Heterologous booster |
Boost ChAdOx1/prime vaccination BNT162b2 or mRNA-1273 |
Boost BNT162b2 or mRNA-1273/prime vaccination BNT162b2 or mRNA-1273 |
RCT2 | Adults under current rituximab therapy who did not develop humoral response against SARS-CoV-2 after their standard vaccination with Biontech/Pfizer or Moderna in a single center in Austria | N= 60 |
Some concerns Details |
|
|
NCT05289037 Moderna + National Institute of Allergy and Infections Diseases (NIAID); ModernaTX Branche A, medRxiv, 2022 a Full text Commentary Commentary Commentary |
RNA based vaccine |
Any COVID-19 vaccine prime and 1st boost/2nd boost mRNA-1273 Omicron + mRNA-1273 Beta Any COVID-19 vaccine prime and 1st boost/2nd boost mRNA-1273Omicron + mRNA-1273 Delta Any COVID-19 vaccine prime and 1st boost/2nd boost mRNA-1273 Omicron + mRNA-1273 Any COVID-19 vaccine prime and 1st boost/2nd boost mRNA-1273 Omicron |
Any COVID-19 vaccine prime and 1st boost/2nd boost mRNA-1273 |
RCTPhase 2 | Adults with completed primary and booster COVID-19 vaccine series, either homologous or heterologous, and in stable health at 22 centers in USA. | N= 602 |
Some concerns Details |
|
|
TCTR20211102003 Sinovac Research and Development Co., Ltd; Pfizer/BioNTech + Fosun Pharma; Moderna + National Institute of Allergy and Infectious Diseases (NIAID); AstraZeneca + University of Oxford Bruminhent J, Am J Transplant, 2022 Full text Full text Commentary |
RNA based vaccine |
CoronaVac or ChAdOx1/Boost BNT162b2 or mRNA-1273 |
CoronaVac or ChAdOx1/Boost ChAdOx1 |
RCTPhase 3 | Adult kidney transplant recipients without a history of COVID-19 in a single centre in Thailand. | N= 85 |
Some concerns Details |
|
|
NCT05132855 Pfizer/BioNTech+Fosun Pharma; Moderna;Medigen Vaccine Biologics+Dynavax+NIAID Chuang C-H, J Clin Virol, 2022 Full text Full text Commentary Commentary |
Heterologous booster |
ChadOx1/Boost BNT162b2 ChadOx1/Boost mRNA-1273 (half dose) ChadOx1/Boost mRNA-1273 |
ChadOx1/boost MVC-COV1901 |
RCT1-2 | Health care worker with no history of COVID-19 who had received 2 prime doses of ChAdOx1 nCoV-19 in a single centre in Taiwan. | N= 340 |
Some concerns Details |
|
|
NCT04796896 ModernaTX Creech CB, N Engl J Med, 2022 KidCOVE Full text Commentary |
RNA based vaccine |
mRNA-1273 (50 mcg D0/28) |
Placebo |
RCTPhase 2-3 | Children aged 6-11 years, healthy or with stable chronic conditions and no known recent history of COVID-19 infection, at 87 centers in Canada and USA. | N= 4016 |
Some concerns Details |
|
|
NCT04470427 ModernaTX El Sahly H, N Engl J Med, 2021 COVE Full text Full text Commentary Commentary |
RNA based vaccine |
mRNA-1273 100 mcg D1/28 |
Placebo D1/28 |
RCTPhase 3 | Healthy adults with no known history of SARS-CoV-2 infection in 99 centers in the US | N= 30415 |
Some concerns Details |
|
|
NCT05197153 AstraZeneca+University of Oxford; Moderna TX; Medigen Vaccine Biologics+Dynavax+NIAID Estephan L, Vaccine, 2023 a Full text Commentary |
Protein subunit |
MVC-COV1901/Boost 1/2 MVC-COV1901 MVC-COV1901/Boost mRNA-127 MVC-COV1901/Boost ChAdOx1 |
MVC-COV1901/Boost MVC-COV1901 |
RCTPhase 2 | Adults who received ChAdOx1, mRNA-1273, or MVC-COV1901 as prime vaccination with no history of COVID-19 , in 4 centers in Taiwan | N= 313 |
Some concerns Details |
|
|
NCT05197153 AstraZeneca+University of Oxford; Moderna TX; Medigen Vaccine Biologics+Dynavax+NIAID Estephan L, Vaccine, 2023 b Full text Commentary |
Protein subunit |
ChadOx1/boost MVC-COV1901 ChadOx1/boostmRNA-1273 (half dose) |
ChadOx1/boostChadOx1 |
RCTPhase 2 | Adults who received ChAdOx1, mRNA-1273, or MVC-COV1901 as prime vaccination with no history of COVID-19 , in 4 centers in Taiwan | N= 323 |
Some concerns Details |
|
|
NCT05197153 AstraZeneca+University of Oxford; Moderna TX; Medigen Vaccine Biologics+Dynavax+NIAID Estephan L, Vaccine, 2023 c Full text Commentary |
Protein subunit |
mRNA-1273/Boost MVC-COV1901 mRNA-1273/Boost ChAdOx1 mRNA-1273/Boost 1/2 MVC-COV1901 |
mRNA-1273/Boost 1/2 mRNA-1273 |
RCTPhase 2 | Adults who received ChAdOx1, mRNA-1273, or MVC-COV1901 as prime vaccination with no history of COVID-19 , in 4 centers in Taiwan | N= 163 |
Some concerns Details |
|
|
NCT04885907 ModernaTX Hall VG, N Engl J Med, 2021 Full text Commentary Commentary |
RNA based vaccine |
mRNA-1273 |
Placebo |
RCTPhase 4 | Solid organ transplant recipients with no previous diagnosis of COVID-19 who has previously received two doses of mRNA-1273 at a single center in Canada | N= 120 |
Some concerns Details |
|
|
NCT04900467; EudraCT: 2021-002174-52 Moderna;Pfizer/BioNTech Janssen C, EClinicalMedicine, 2022 Full text Full text Commentary |
Heterologous vaccination scheme |
1 dose BNT162b2/1 dose mRNA-1273 1 dose mRNA-1273 /1 dose BNT162b2 |
2 doses BNT162b2 2 doses mRNA-1273 |
RCTPhase 2 | Adults with no known or suspected history of SARS-CoV-2 infection at 17 centers in France. | N= 414 |
Some concerns Details |
|
|
NCT05030974 Moderna ; Pfizer/BioNTech + Fosun Pharma ; Janssen Pharmaceutical Kho M, Lancet Infect Dis, 2022 RECOVAC Full text Commentary Commentary |
Heterologous booster |
mRNA vaccine/Boost 2 doses mRNA-1273 mRNA vaccine/Boost Ad26.COV2-S |
mRNAvaccine/Boost mRNA-1273 |
RCTPhase 4 | Adult kidney transplant recipients without seroconversion after two doses of an mRNA vaccine and no history of COVID-19 at 4 centers in the Netherlands. | N= 230 |
Some concerns Details |
|
|
EudraCT, 2022-000063-51; NCT05249829 ModernaTX/ National Institute of Allergy and Infectious Diseases (NIAID) Lee I, medRxiv, 2023 a Full text Commentary Commentary |
Heterologous booster |
Any prime vaccine/Boost mRNA vaccine/ mRNA-1273.529 |
Any prime vaccine/Boost mRNA vaccine/ mRNA-1273 |
RCTPhase 2-3 | Healthy or stable co-morbidities, at least 16 years who had previously received 2 injections of an authorized Covid-19 primary series vaccine with or without an mRNA-based booster as the third dose in 28 centres in UK. | N= 724 |
Some concerns Details |
|
|
EudraCT, 2022-000063-51; NCT05249829 ModernaTX/National Institute of Allergy and Infectious Diseases (NIAID) Lee l, medRxiv, 2023 b Full text Commentary Commentary |
Heterologous booster |
Any prime vaccine/Boost mRNA vaccine/ mRNA-1273.214 |
Any prime vaccine/Boost mRNA vaccine/ mRNA-1273 |
RCTPhase 2-3 | Healthy or stable co-morbidities, at least 16 years who had previously received 2 injections of an authorized Covid-19 primary series vaccine with or without an mRNA-based booster as the third dose in 28 centres in UK. | N= 2,824 |
Some concerns Details |
|
|
NCT04962906; NCT05027672 Gamaleya Research Institute, AstraZeneca+University of Oxford;Moderna;Sinopharm Macchia A, Lancet Reg Health Am, 2022 Full text Commentary |
Non replicating viral vector |
Gam-COVID-Vac rAd26-S |
Gam-COVID-Vac rAd26-S/BBIBP-CorV |
RCTPhase 2 | Adults who had received the first dose (rAd26) of the Sputnik V vaccine at least 30 days earlier and no history of SARS-CoV-2 at a single centre in Argentina | N= 540 |
Some concerns Details |
|
|
NCT04677660 ModernaTX Masuda T, Vaccine, 2022 a Full text Commentary |
RNA based vaccine |
mRNA-1273 |
Placebo |
RCTPhase 1-2 | Healthy adults aged ≥ 20 years with no known history/risk of SARS-CoV-2 infection at 2 centers in Japan. | N= 200 |
Some concerns Details |
|
|
EudraCT 2021-002693-10 Moderna+NIAID; Pfizer/BioNTech+Fosun Pharma; AstraZeneca + University of Oxford Mrak D, Nat Commun, 2022 Full text Commentary Commentary |
Homologous booster |
BNT162b2 or mRNA-1273/Boost ChAdOx1 |
mRNA-1273 or BNT162b2/Homologous boost |
RCTPhase 2 | Immunosuppressed adults including elderly with no history of COVID-19 in a single centre in Austria. | N= 51 |
Low Details |
|
|
ISRCTN73765130 AstraZeneca + University of Oxford; Janssen Pharmaceutical; Novovax; Moderna + NIAID; Pfizer BioNTech + Fosun Pharma; CureVac AG; Valneva, NIHR, UK Munro A, Lancet, 2021 e COV-BOOST Full text Commentary |
Heterologous booster |
ChadOx1/Boost mRNA1273 ChadOx1/Boost CVnCov ChadOx1/Boost BNT162b2 half dose |
ChadOx1/Boost placebo |
RCTPhase 2 | Adults aged ≥30 years in good physical health at 18 centers in the UK. | N= 2883 |
Some concerns Details |
|
|
ISRCTN73765130 AstraZeneca + University of Oxford; Janssen Pharmaceutical; Novovax; Moderna + NIAID; Pfizer BioNTech + Fosun Pharma; CureVac AG; Valneva, NIHR, UK Munro A, Lancet, 2021 b COV-BOOST Full text Commentary |
Heterologous booster |
BNT162b2/Boost ChAdOx1 BNT162b2/Boost Novavax BNT162b2/Boost Novavax half dose |
BNT162b2/Boost placebo |
RCTPhase 2 | Adults aged ≥30 years in good physical health at 18 centers in the UK. | N= 2883 |
Some concerns Details |
|
|
ISRCTN73765130 AstraZeneca + University of Oxford; Janssen Pharmaceutical; Novovax; Moderna + NIAID; Pfizer BioNTech + Fosun Pharma; CureVac AG; Valneva, NIHR, UK Munro A, Lancet, 2021 f COV-BOOST Full text Commentary |
Heterologous booster |
BNT162b2/Boost mRNA1273 BNT162b2/Boost CVnCov BNT162b2/Boost BNT162b2 half dose |
BNT162b2/Boos placebo |
RCTPhase 2 | Adults aged ≥30 years in good physical health at 18 centers in the UK. | N= 2883 |
Some concerns Details |
|
|
ISRCTN73765130 AstraZeneca + University of Oxford; Janssen Pharmaceutical; Novovax; Moderna + NIAID; Pfizer BioNTech + Fosun Pharma; CureVac AG; Valneva, NIHR, UK Munro A, Lancet, 2021 c COV-BOOST Full text Commentary |
Heterologous booster |
ChadOx1/Boost BNT162b2 ChadOx1/Boost VLA2001 ChadOx1/Boost VLA2001 half dose ChadOx1/Boost Ad26.COV2.S |
ChadOx1/Boost placebo |
RCTPhase 2 | Adults aged ≥30 years in good physical health at 18 centers in the UK. | N= 2883 |
Some concerns Details |
|
|
ISRCTN73765130 AstraZeneca + University of Oxford; Janssen Pharmaceutical; Novovax; Moderna + NIAID; Pfizer BioNTech + Fosun Pharma; CureVac AG; Valneva, NIHR, UK Munro A , Lancet, 2021 a COV-BOOST Full text Commentary |
Non replicating viral vector |
ChadOx1/Boost ChadOx1 ChadOx1/Boost Novavax ChadOx1/Boost Novavax ChadOx1/Boost Novavax half dose ChadOx1/Boost Novavax half dose |
ChadOx1/Boost Placebo ChadOx1/Boost Placebo ChadOx1/Boost ChadOx1 ChadOx1/Boost ChadOx1 ChadOx1/Boost Placebo |
RCTPhase 2 | Adults aged ≥30 years in good physical health at 18 centers in the UK. | N= 2883 |
Some concerns Details |
|
|
ISRCTN73765130 AstraZeneca + University of Oxford; Janssen Pharmaceutical; Novovax; Moderna + NIAID; Pfizer BioNTech + Fosun Pharma; CureVac AG; Valneva, NIHR, UK Munro A, Lancet, 2021 d COV-BOOST Full text Commentary |
RNA based vaccine |
BNT162b2/Boost BNT162b2 BNT162b2/Boost VLA2001 BNT162b2/Boost VLA2001 half dose BNT162b2/Boost Ad26.COV2.S |
BNT162b2/Boost placebo |
RCTPhase 2 | Adults aged ≥30 years in good physical health at 18 centers in the UK. | N= 2883 |
Some concerns Details |
|
|
ISRCTN73765130 ; EudraCT 2021-002175-19 Pfizer/BioNTech;ModernaTX Munro APS, Lancet Infect Dis, 2022 COV-BOOST Full text Commentary |
RNA based vaccine |
BNT162b2/1st boost BNT162b2/2nd boost BNT162b2 ChadOx1/1st boost BNT162b2/2nd boost BNT162b2 |
BNT162b2/1st boost BNT162b2/2nd boost half dose m-RNA 1273 ChadOx1/1st boost BNT162b2/2nd boost half dose m-RNA 1273 |
RCTPhase 2 | Healthy adults aged 30 years or over, including elderly and those with well controlled or mild-moderate comorbidity, who had received a 2-dose primary schedule of either BNT162b2 or ChAdOx1 and a BNT162b2 booster at 18 centers in the UK | N= 166 |
Some concerns Details |
|
|
NCT05142319 Pfizer/BioNTech+Fosun Pharma; ModernaTX Poh XY, Clin. Infect. Dis., 2022 PRIBIVAC Full text Commentary |
RNA based vaccine |
BNT162b2/Boost mRNA-1273 |
BNT162b2/Boost BNT162b2 |
RCT3 | Adults at a single center in Singapore with no previous history of COVID-19 who had received a primary series of BTN162b2 at least 6 months previously | N= 100 |
Some concerns Details |
|
|
EudraCT021-002927-39 Pfizer/BioNTech+Fosun Pharma/Moderna/Janssen Pharmaceutical Companies Reindl-Schwaighofer R, JAMA, 2021 Full text Full text Commentary Commentary |
RNA based vaccine |
mRNA-1273 or BNT162b2/Homologous boost |
mRNA-1273 or BNT162b2/Boost Ad26COVS1 |
RCTPhase 2 | Adult kidney transplant recipients with no history of COVID-19 infection and without an antibody response 4 weeks after a 2-dose mRNA vaccine schedule at a single center in Austria. | N= 201 |
Some concerns Details |
|
|
NCT04927936 Janssen Pharmaceutical;Moderna ;Pfizer/BionTech+Fosun Pharma Sablerolles R, Clin Infect Dis, 2022 SWITCH Full text Full text Commentary Commentary |
Placebo |
Ad26.COV2.S/Boost m-RNA-1273 Ad26.COV2.S/Boost BNT162b2 |
Ad26.COV2.S/Boost Ad26.COV2.S |
RCTPhase 3 | Healthcare workers aged 18-65 years, without severe comorbidities, and no known history of SARS-CoV-2 infection who received a single Ad26.COV2.S primary vaccination at 4 centers in the Netherlands. | N= 461 |
Some concerns Details |
|
|
NCT04805125 Pfizer/BioNTech+Fosun Pharma; ModernaTX Speich B, Clin Infect Dis, 2022 Full text Full text Commentary Commentary |
RNA based vaccine |
BNT162b2 |
mRNA-1273 |
RCTPhase 3 | Adult patients living with HIV (PLWH) or solid organ transplant recipients who were SARS-CoV-2 infection-free for the last 3 months in 3 centres in Switzerland. | N= 430 |
Some concerns Details |
|
|
ISRCTN27841311; EudraCT 2021-001275-16 AstraZeneca + University of Oxford / Novavax / Moderna + NIAID Stuart A, Lancet, 2021 a Com-COV2 Full text Commentary Commentary |
Protein subunit |
1 dose ChAdOx1 followed by 1 dose NVX-CoV2373 1 dose ChAdOx1 followed by 1 dose mRNA-1273 |
2 doses ChAdOx1 |
RCTPhase 2 | Healthy adults over 50 years previously vaccinated with one dose of ChAdOx1 nCoV-19 in 9 centres in the UK | N= 540 |
Some concerns Details |
|
|
ISRCTN27841311; EudraCT 2021-001275-16 Pfizer BioNTech + Fosun Pharma / Novavax / Moderna + NIAID Stuart A, Lancet, 2021 b Com-COV2 Full text Commentary Commentary |
Protein subunit |
1 dose BNT162b2 followed by 1 dose NVX-CoV2373 1 dose BNT162b2 followed by 1 dose mRNA-1273 |
2 doses BNT162b2 |
RCTPhase 2 | Adults over 50 years previously vaccinated with one dose of BNT162b2 at 9 centres in the UK | N= 532 |
Some concerns Details |
|